Covid Vaccine Scientific Proof
Covid Vaccine Scientific Proof
Over One Thousand Scientific Studies Prove That the COVID-19 Vaccines Are Dangerous, and All Those
Pushing This Agenda Are Committing the Indictable Crime of Gross Misconduct in Public Office
Just over 12 months from deployment of the COVID 19 emergency use experimental vaccines, scientific
studies in the thousands, and reports of criminal complaints of assault and murder from the illegal,
unlawful use of biochemical poisons made to police forces around the country, verify an assault on an
unsuspecting UK population. Irrefutable science shows that the COVID 19 vaccine is not safe and not
effective in limiting transmission or infection from the SARS-CoV-2, coronavirus pathogens.
The “safe and effective” false propaganda, put out by public officials who now are continuing to push
this vaccine, is a clear breach of duty. A public office holder is subject to, and aware of, a duty to prevent
death or serious injury that arises only by virtue of the functions of the public office.
Many have breached that duty and, in doing so, are recklessly causing a risk of death or serious injury,
by carrying on regardless of the now-confirmed dangers associated with COVID 19 injections. Some of
these risks are blood clotting, myocarditis, pericarditis, thrombosis, thrombocytopenia, anaphylaxis,
Bell’s palsy, Guillain-Barre, cancer including deaths, etc.
All of these are confirmed in the following science-and-government-gathered data from the UK Health
and Security agency on COVID 19 regarding vaccine damage.
The term “vaccine” was changed recently to incorporate this illegal, unlawful medical experiment to
facilitate usage of mRNA technology that is demonstrably not a vaccine, and which contains biologically
toxic nano-metamaterials associated with 5G urban data gathering capability.
Metal nanoparticulates are known in science to be genotoxic—a poison that can also cause sterilization.
The dangers posed to the victims in the near term from this medical battery are now known. However,
the long term lethality of this weapon is not as yet realized due to the debilitating effects it has on the
immune system, causing Acquired Immunodeficiency Syndrome(AIDS).
We can now confirm the 2017 depopulation defence-intelligence documents, showing the planned
murder of over 55 million across the United Kingdom by 2025 using this biochemical weapon.
The Medicines and Healthcare (products) Regulatory Agency (MHRA) had prior warning of the expected
large numbers of adverse reactions before the deployment—confirming the premeditated nature of the
crime and public conduct offences then and now.
1. Cerebral venous thrombosis after COVID-19 vaccination in the UK: a multicentre cohort
study: https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(21)01608-1/
5. Three cases of acute venous thromboembolism in women after vaccination against COVID-
19: https://www.sciencedirect.com/science/article/pii/S2213333X21003929
7. US case reports of cerebral venous sinus thrombosis with thrombocytopenia after vaccination
with Ad26.COV2.S (against covid-19), March 2 to April 21,
2020: https://pubmed.ncbi.nlm.nih.gov/33929487/
10. Vaccine-induced immune immune thrombotic thrombocytopenia and cerebral venous sinus
thrombosis after vaccination with COVID-19; a systematic
review: https://www.sciencedirect.com/science/article/pii/S0022510X21003014
13. Thrombosis with thrombocytopenia syndrome associated with COVID-19 viral vector
vaccines: https://www.sciencedirect.com/science/article/abs/pii/S0953620521001904
17. Cerebral venous sinus thrombosis after vaccination: the United Kingdom
experience: https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(21)01788-
8/fulltext
19. Myocarditis after immunization with COVID-19 mRNA vaccines in members of the US military.
This article reports that in “23 male patients, including 22 previously healthy military members,
myocarditis was identified within 4 days after receipt of the
vaccine”: https://jamanetwork.com/journals/jamacardiology/fullarticle/2781601
21. Association of myocarditis with the BNT162b2 messenger RNA COVID-19 vaccine in a case series
of children: https://pubmed.ncbi.nlm.nih.gov/34374740/
26. Aphasia seven days after the second dose of an mRNA-based SARS-CoV-2 vaccine. Brain MRI
revealed an intracerebral hemorrhage (ICBH) in the left temporal lobe in a 52-year-old
man. https://www.sciencedirect.com/science/article/pii/S2589238X21000292#f0005
29. Blood clots and bleeding episodes after BNT162b2 and ChAdOx1 nCoV-19 vaccination: analysis
of European data: https://www.sciencedirect.com/science/article/pii/S0896841121000937
31. Primary adrenal insufficiency associated with thrombotic immune thrombocytopenia induced by
the Oxford-AstraZeneca ChAdOx1 nCoV-19 vaccine
(VITT): https://www.sciencedirect.com/science/article/pii/S0953620521002363
32. Myocarditis and pericarditis after vaccination with COVID-19 mRNA: practical considerations for
care providers: https://www.sciencedirect.com/science/article/pii/S0828282X21006243
33. “Portal vein thrombosis occurring after the first dose of SARS-CoV-2 mRNA vaccine in a patient
with antiphospholipid
syndrome”: https://www.sciencedirect.com/science/article/pii/S2666572721000389
34. Early results of bivalirudin treatment for thrombotic thrombocytopenia and cerebral venous
sinus thrombosis after vaccination with
Ad26.COV2.S: https://www.sciencedirect.com/science/article/pii/S0196064421003425
39. Cerebral venous sinus thrombosis negative for anti-PF4 antibody without thrombocytopenia
after immunization with COVID-19 vaccine in a non-comorbid elderly Indian male treated with
conventional heparin-warfarin based
anticoagulation: https://www.sciencedirect.com/science/article/pii/S1871402121002046
41. Cerebral venous sinus thrombosis in the U.S. population after SARS-CoV-2 vaccination with
adenovirus and after COVID-
19: https://www.sciencedirect.com/science/article/pii/S0735109721051949
42. A rare case of a middle-aged Asian male with cerebral venous thrombosis after AstraZeneca
COVID-19 vaccination: https://www.sciencedirect.com/science/article/pii/S0735675721005714
43. Cerebral venous sinus thrombosis and thrombocytopenia after COVID-19 vaccination: report of
two cases in the United
Kingdom: https://www.sciencedirect.com/science/article/abs/pii/S088915912100163X
44. Immune thrombocytopenic purpura after vaccination with COVID-19 vaccine (ChAdOx1 nCov-
19): https://www.sciencedirect.com/science/article/abs/pii/S0006497121013963.
45. Antiphospholipid antibodies and risk of thrombophilia after COVID-19 vaccination: the straw
that breaks the camel’s
back?: https://docs.google.com/document/d/1XzajasO8VMMnC3CdxSBKks1o7kiOLXFQ
46. Vaccine-induced thrombotic thrombocytopenia, a rare but severe case of friendly fire in the
battle against the COVID-19 pandemic: What
pathogenesis?: https://www.sciencedirect.com/science/article/pii/S0953620521002314
47. Diagnostic-therapeutic recommendations of the ad-hoc FACME expert working group on the
management of cerebral venous thrombosis related to COVID-19
vaccination: https://www.sciencedirect.com/science/article/pii/S0213485321000839
48. Thrombocytopenia and intracranial venous sinus thrombosis after exposure to the “AstraZeneca
COVID-19 vaccine”: https://pubmed.ncbi.nlm.nih.gov/33918932/
52. COVID-19 vaccination: information on the occurrence of arterial and venous thrombosis using
data from VigiBase: https://pubmed.ncbi.nlm.nih.gov/33863748/
54. Cerebral venous thrombosis following BNT162b2 mRNA vaccination of BNT162b2 against SARS-
CoV-2: a black swan event: https://pubmed.ncbi.nlm.nih.gov/34133027/
57. Blood clots and bleeding after BNT162b2 and ChAdOx1 nCoV-19 vaccination: an analysis of
European data: https://pubmed.ncbi.nlm.nih.gov/34174723/
58. First dose of ChAdOx1 and BNT162b2 COVID-19 vaccines and thrombocytopenic,
thromboembolic, and hemorrhagic events in
Scotland: https://www.nature.com/articles/s41591-021-01408-4
60. First report of a de novo iTTP episode associated with a COVID-19 mRNA-based anti-COVID-19
vaccine: https://pubmed.ncbi.nlm.nih.gov/34105244/
68. Temporal association between COVID-19 vaccine Ad26.COV2.S and acute myocarditis: case
report and review of the
literature: https://www.sciencedirect.com/science/article/pii/S1553838921005789
70. Potential association between COVID-19 vaccine and myocarditis: clinical and CMR
findings: https://www.sciencedirect.com/science/article/pii/S1936878X2100485X
71. Recurrence of acute myocarditis temporally associated with receipt of coronavirus mRNA
disease vaccine 2019 (COVID-19) in a male
adolescent: https://www.sciencedirect.com/science/article/pii/S002234762100617X
72. Fulminant myocarditis and systemic hyper inflammation temporally associated with BNT162b2
COVID-19 mRNA vaccination in two
patients: https://www.sciencedirect.com/science/article/pii/S0167527321012286.
73. Acute myocarditis after administration of BNT162b2
vaccine: https://www.sciencedirect.com/science/article/pii/S2214250921001530
76. Acute myocarditis after Comirnaty (Pfizer) vaccination in a healthy male with previous SARS-
CoV-2 infection: https://www.sciencedirect.com/science/article/pii/S1930043321005549
80. Temporal relationship between the second dose of BNT162b2 mRNA Covid-19 vaccine and
cardiac involvement in a patient with previous SARS-COV-2
infection: https://www.sciencedirect.com/science/article/pii/S2352906721000622
83. Important information on myopericarditis after vaccination with Pfizer COVID-19 mRNA in
adolescents: https://www.sciencedirect.com/science/article/pii/S0022347621007496
84. A series of patients with myocarditis after vaccination against SARS-CoV-2 with mRNA-1279 and
BNT162b2: https://www.sciencedirect.com/science/article/pii/S1936878X21004861
88. Epidemiology and clinical features of myocarditis/pericarditis before the introduction of COVID-
19 mRNA vaccine in Korean children: a multicenter study https://search.bvsalud.org/global-
literature-on-novel-coronavirus-2019-ncov/resourc e/en/covidwho-1360706.
94. Association of myocarditis with COVID-19 messenger RNA vaccine BNT162b2 in a case series of
children: https://jamanetwork.com/journals/jamacardiology/fullarticle/2783052
95. Myocarditis after immunization with COVID-19 mRNA vaccines in members of the U.S.
military: https://jamanetwork.com/journals/jamacardiology/fullarticle/2781601%5C
101. Cardiovascular magnetic resonance imaging findings in young adult patients with acute
myocarditis after COVID-19 mRNA vaccination: a case series: https://jcmr-
online.biomedcentral.com/articles/10.1186/s12968-021-00795-4
102. Clinical Guidance for Young People with Myocarditis and Pericarditis after Vaccination
with COVID-19 mRNA: https://www.cps.ca/en/documents/position/clinical-guidance-for-youth-
with-myocarditis-and-pericarditis
104. Case report: acute myocarditis after second dose of mRNA-1273 SARS-CoV-2 mRNA
vaccine: https://academic.oup.com/ehjcr/article/5/8/ytab319/6339567
108. The new COVID-19 mRNA vaccine platform and myocarditis: clues to the possible
underlying mechanism: https://pubmed.ncbi.nlm.nih.gov/34312010/
109. Acute myocardial injury after COVID-19 vaccination: a case report and review of current
evidence from the Vaccine Adverse Event Reporting System
database: https://pubmed.ncbi.nlm.nih.gov/34219532/
112. In-depth evaluation of a case of presumed myocarditis after the second dose of COVID-
19 mRNA vaccine: https://www.ahajournals.org/doi/10.1161/CIRCULATIONAHA.121.056038
116. Self-limited myocarditis presenting with chest pain and ST-segment elevation in
adolescents after vaccination with the BNT162b2 mRNA
vaccine: https://pubmed.ncbi.nlm.nih.gov/34180390/
118. Biopsy-proven lymphocytic myocarditis after first COVID-19 mRNA vaccination in a 40-
year-old man: case report: https://pubmed.ncbi.nlm.nih.gov/34487236/
121. Perimyocarditis after the first dose of mRNA-1273 SARS-CoV-2 (Modern) mRNA-1273
vaccine in a young healthy male: case
report: https://bmccardiovascdisord.biomedcentral.com/articles/10.1186/s12872-021-02183
122. Acute myocarditis after the second dose of SARS-CoV-2 vaccine: serendipity or causal
relationship: https://pubmed.ncbi.nlm.nih.gov/34236331/
125. GM1 ganglioside antibody and COVID-19-related Guillain Barre syndrome: case report,
systemic review, and implications for vaccine
development: https://www.sciencedirect.com/science/article/pii/S2666354621000065
127. Sensory Guillain-Barré syndrome after ChAdOx1 nCov-19 vaccine: report of two cases
and review of the
literature: https://www.sciencedirect.com/science/article/pii/S0165572821002186
128. Guillain-Barré syndrome after the first dose of SARS-CoV-2 vaccine: a temporary
occurrence, not a causal
association: https://www.sciencedirect.com/science/article/pii/S2214250921000998.
129. Guillain-Barré syndrome presenting as facial diplegia after vaccination with COVID-19: a
case report: https://www.sciencedirect.com/science/article/pii/S0736467921006442
130. Guillain-Barré syndrome after the first injection of ChAdOx1 nCoV-19 vaccine: first
report: https://www.sciencedirect.com/science/article/pii/S0035378721005853.
131. SARS-CoV-2 vaccines are not safe for those with Guillain-Barre syndrome following
vaccination: https://www.sciencedirect.com/science/article/pii/S2049080121005343
133. Facial nerve palsy following administration of COVID-19 mRNA vaccines: analysis of self-
report database: https://www.sciencedirect.com/science/article/pii/S1201971221007049
138. Bell’s palsy after the second dose of the Pfizer COVID-19 vaccine in a patient with a
history of recurrent Bell’s
palsy: https://www.sciencedirect.com/science/article/pii/S266635462100020X
139. Acute-onset central serous retinopathy after immunization with COVID-19 mRNA
vaccine:. https://www.sciencedirect.com/science/article/pii/S2451993621001456.
141. An academic hospital experience assessing the risk of COVID-19 mRNA vaccine using
patient’s allergy
history: https://www.sciencedirect.com/science/article/pii/S2213219821007972
146. Clinical and pathologic correlates of skin reactions to COVID-19 vaccine, including V-
REPP: a registry-based
study: https://www.sciencedirect.com/science/article/pii/S0190962221024427
149. Cerebral venous sinus thrombosis negative for anti-PF4 antibody without
thrombocytopenia after immunization with COVID-19 vaccine in an elderly, non-comorbid
Indian male treated with conventional heparin-warfarin-based
anticoagulation:. https://www.sciencedirect.com/science/article/pii/S1871402121002046.
150. Acute myocarditis after administration of BNT162b2 vaccine against COVID-
19:. https://www.sciencedirect.com/science/article/abs/pii/S188558572100133X
151. Blood clots and bleeding after BNT162b2 and ChAdOx1 nCoV-19 vaccine: an analysis of
European data:. https://www.sciencedirect.com/science/article/pii/S0896841121000937.
153. Bullous drug eruption after the second dose of COVID-19 mRNA-1273 (Moderna)
vaccine: Case report: https://www.sciencedirect.com/science/article/pii/S1876034121001878.
155. This study notes that 115 pregnant women lost their babies, out of 827 who
participated in a study on the safety of covid-19
vaccines: https://www.nejm.org/doi/full/10.1056/NEJMoa2104983.
158. Allergic reactions, including anaphylaxis, after receiving the first dose of the Pfizer-
BioNTech COVID-19 vaccine: https://pubmed.ncbi.nlm.nih.gov/33475702/
159. Allergic reactions to the first COVID-19 vaccine: a potential role of polyethylene
glycol: https://pubmed.ncbi.nlm.nih.gov/33320974/
161. Allergic reactions, including anaphylaxis, after receiving the first dose of Pfizer-BioNTech
COVID-19 vaccine – United States, December 14-23,
2020: https://pubmed.ncbi.nlm.nih.gov/33444297/
162. Allergic reactions, including anaphylaxis, after receiving first dose of Modern COVID-19
vaccine – United States, December 21, 2020-January 10,
2021: https://pubmed.ncbi.nlm.nih.gov/33507892/
163. Reports of anaphylaxis after coronavirus disease vaccination 2019, South Korea,
February 26-April 30, 2021: https://pubmed.ncbi.nlm.nih.gov/34414880/
164. Reports of anaphylaxis after receiving COVID-19 mRNA vaccines in the U.S.-Dec 14,
2020-Jan 18, 2021: https://pubmed.ncbi.nlm.nih.gov/33576785/
168. Severe Allergic Reactions after COVID-19 Vaccination with the Pfizer / BioNTech Vaccine
in Great Britain and the USA: Position Statement of the German Allergy Societies: German
Medical Association of Allergologists (AeDA), German Society for Allergology and Clinical
Immunology (DGAKI) and Society for Pediatric Allergology and Environmental Medicine
(GPA): https://pubmed.ncbi.nlm.nih.gov/33643776/
170. Reported orofacial adverse effects from COVID-19 vaccines: the known and the
unknown: https://pubmed.ncbi.nlm.nih.gov/33527524/
172. Cumulative adverse event report of anaphylaxis following injections of COVID-19 mRNA
vaccine (Pfizer-BioNTech) in Japan: the first month
report: https://pubmed.ncbi.nlm.nih.gov/34347278/
174. Biphasic anaphylaxis after exposure to the first dose of the Pfizer-BioNTech COVID-19
mRNA vaccine COVID-19: https://pubmed.ncbi.nlm.nih.gov/34050949/
175. Allergenic components of the mRNA-1273 vaccine for COVID-19: possible involvement
of polyethylene glycol and IgG-mediated complement
activation: https://pubmed.ncbi.nlm.nih.gov/33657648/
176. Polyethylene glycol (PEG) is a cause of anaphylaxis to Pfizer / BioNTech mRNA COVID-19
vaccine: https://pubmed.ncbi.nlm.nih.gov/33825239/
178. Polyethylene glycole allergy of the SARS CoV2 vaccine recipient: case report of a young
adult recipient and management of future exposure to SARS-
CoV2: https://pubmed.ncbi.nlm.nih.gov/33919151/
179. Elevated rates of anaphylaxis after vaccination with Pfizer BNT162b2 mRNA vaccine
against COVID-19 in Japanese healthcare workers; a secondary analysis of initial post-approval
safety data: https://pubmed.ncbi.nlm.nih.gov/34128049/
180. Allergic reactions and adverse events associated with administration of mRNA-based
vaccines. A health system experience: https://pubmed.ncbi.nlm.nih.gov/34474708/
181. Allergic reactions to COVID-19 vaccines: statement of the Belgian Society of Allergy and
Clinical Immunology
(BelSACI): https://www.tandfonline.com/doi/abs/10.1080/17843286.2021.1909447
184. Anaphylactic reactions to COVID-19 mRNA vaccines: a call for further studies:
https://pubmed.ncbi.nlm.nih.gov/33846043/ 188.
185. Risk of severe allergic reactions to COVID-19 vaccines among patients with allergic skin
disease: practical recommendations. An ETFAD position statement with external
experts: https://pubmed.ncbi.nlm.nih.gov/33752263/
186. COVID-19 vaccine and death: causality algorithm according to the WHO eligibility
diagnosis: https://pubmed.ncbi.nlm.nih.gov/34073536/
188. A case series of skin reactions to COVID-19 vaccine in the Department of Dermatology at
Loma Linda University: https://pubmed.ncbi.nlm.nih.gov/34423106/
189. Skin reactions reported after Moderna and Pfizer’s COVID-19 vaccination: a study based
on a registry of 414 cases: https://pubmed.ncbi.nlm.nih.gov/33838206/
190. Clinical and pathologic correlates of skin reactions to COVID-19 vaccine, including V-
REPP: a registry-based study: https://pubmed.ncbi.nlm.nih.gov/34517079/
191. Skin reactions after vaccination against SARS-COV-2: a nationwide Spanish cross-
sectional study of 405 cases: https://pubmed.ncbi.nlm.nih.gov/34254291/
192. Varicella zoster virus and herpes simplex virus reactivation after vaccination with COVID-
19: review of 40 cases in an international dermatologic
registry: https://pubmed.ncbi.nlm.nih.gov/34487581/
193. Immune thrombosis and thrombocytopenia (VITT) associated with the COVID-19
vaccine: diagnostic and therapeutic recommendations for a new
syndrome: https://pubmed.ncbi.nlm.nih.gov/33987882/
198. Nerve and muscle adverse events after vaccination with COVID-19: a systematic review
and meta-analysis of clinical trials: https://pubmed.ncbi.nlm.nih.gov/34452064/.
199. A rare case of cerebral venous thrombosis and disseminated intravascular coagulation
temporally associated with administration of COVID-19
vaccine: https://pubmed.ncbi.nlm.nih.gov/33917902/
201. Acute cerebral venous thrombosis and pulmonary artery embolism associated with the
COVID-19 vaccine: https://pubmed.ncbi.nlm.nih.gov/34247246/.
203. 59-year-old woman with extensive deep venous thrombosis and pulmonary
thromboembolism 7 days after a first dose of Pfizer-BioNTech BNT162b2 mRNA vaccine COVID-
19: https://pubmed.ncbi.nlm.nih.gov/34117206/
207. Unusual presentation of acute pericarditis after vaccination against SARS-COV-2 mRNA-
1237 Modern: https://pubmed.ncbi.nlm.nih.gov/34447639/
208. Case report: acute myocarditis after second dose of SARS-CoV-2 mRNA-1273 vaccine
mRNA-1273: https://pubmed.ncbi.nlm.nih.gov/34514306/
210. Insights from a murine model of myopericarditis induced by COVID-19 mRNA vaccine:
could accidental intravenous injection of a vaccine induce
myopericarditis: https://pubmed.ncbi.nlm.nih.gov/34453510/
211. Immune thrombocytopenia in a 22-year-old post Covid-19
vaccine: https://pubmed.ncbi.nlm.nih.gov/33476455/
213. Secondary immune thrombocytopenia (ITP) associated with ChAdOx1 Covid-19 vaccine:
case report: https://pubmed.ncbi.nlm.nih.gov/34377889/
218. Acute transverse myelitis (ATM): clinical review of 43 patients with COVID-19-associated
ATM and 3 serious adverse events of post-vaccination ATM with ChAdOx1 nCoV-19 vaccine
(AZD1222): https://pubmed.ncbi.nlm.nih.gov/33981305/
220. Sequential contralateral facial nerve palsy after first and second doses of COVID-19
vaccine: https://pubmed.ncbi.nlm.nih.gov/34281950/.
222. Peripheral facial nerve palsy after vaccination with BNT162b2 (COVID-
19): https://pubmed.ncbi.nlm.nih.gov/33734623/
224. Facial nerve palsy after administration of COVID-19 mRNA vaccines: analysis of self-
report database: https://pubmed.ncbi.nlm.nih.gov/34492394/
225. Transient oculomotor paralysis after administration of RNA-1273 messenger vaccine for
SARS-CoV-2 diplopia after COVID-19 vaccine: https://pubmed.ncbi.nlm.nih.gov/34369471/
229. Guillian Barré syndrome after vaccination with mRNA-1273 against COVID-
19: https://pubmed.ncbi.nlm.nih.gov/34477091/
231. Bell’s palsy after COVID-19 vaccination with high antibody response in
CSF: https://pubmed.ncbi.nlm.nih.gov/34322761/.
233. Bell’s palsy after a single dose of vaccine mRNA. SARS-CoV-2: case
report: https://pubmed.ncbi.nlm.nih.gov/34032902/.
234. Autoimmune hepatitis developing after coronavirus disease vaccine 2019 (COVID-19):
causality or victim?: https://pubmed.ncbi.nlm.nih.gov/33862041/
238. A novel case of bifacial diplegia variant of Guillain-Barré syndrome after vaccination with
Janssen COVID-19: https://pubmed.ncbi.nlm.nih.gov/34449715/
240. Bilateral superior ophthalmic vein thrombosis, ischemic stroke and immune
thrombocytopenia after vaccination with ChAdOx1 nCoV-
19: https://pubmed.ncbi.nlm.nih.gov/33864750/
241. Diagnosis and treatment of cerebral venous sinus thrombosis with vaccine-induced
immune-immune thrombotic thrombocytopenia: https://pubmed.ncbi.nlm.nih.gov/33914590/
244. Risk of thrombocytopenia and thromboembolism after covid-19 vaccination and positive
SARS-CoV-2 tests: self-controlled case series
study: https://pubmed.ncbi.nlm.nih.gov/34446426/
245. Blood clots and bleeding after BNT162b2 and ChAdOx1 nCoV-19 vaccination: an analysis
of European data: https://pubmed.ncbi.nlm.nih.gov/34174723/
247. First dose of ChAdOx1 and BNT162b2 COVID-19 vaccines and thrombocytopenic,
thromboembolic and hemorrhagic events in
Scotland: https://pubmed.ncbi.nlm.nih.gov/34108714/
249. Malignant cerebral infarction after vaccination with ChAdOx1 nCov-19: a catastrophic
variant of vaccine-induced immune-mediated thrombotic
thrombocytopenia: https://pubmed.ncbi.nlm.nih.gov/34341358/
250. celiac artery and splenic artery thrombosis complicated by splenic infarction 7 days after
the first dose of Oxford vaccine, causal relationship or
coincidence: https://pubmed.ncbi.nlm.nih.gov/34261633/.
253. Cerebral venous sinus thrombosis associated with thrombocytopenia after COVID-19
vaccination: https://pubmed.ncbi.nlm.nih.gov/33845870/.
257. central venous sinus thrombosis with subarachnoid hemorrhage after COVID-19 mRNA
vaccination: are these reports merely coincidental: https://pubmed.ncbi.nlm.nih.gov/34478433/
258. Intracerebral hemorrhage due to thrombosis with thrombocytopenia syndrome after
COVID-19 vaccination: the first fatal case in Korea: https://pubmed.ncbi.nlm.nih.gov/34402235/
259. Cerebral venous sinus thrombosis negative for anti-PF4 antibody without
thrombocytopenia after immunization with COVID-19 vaccine in a non-comorbid elderly Indian
male treated with conventional heparin-warfarin-based
anticoagulation: https://pubmed.ncbi.nlm.nih.gov/34186376/
260. Cerebral venous sinus thrombosis 2 weeks after first dose of SARS-CoV-2 mRNA
vaccine: https://pubmed.ncbi.nlm.nih.gov/34101024/
265. Thrombosis with thrombocytopenia syndrome associated with COVID-19 viral vector
vaccines: https://pubmed.ncbi.nlm.nih.gov/34092488/
266. Pulmonary embolism, transient ischemic attack, and thrombocytopenia after Johnson &
Johnson COVID-19 vaccine: https://pubmed.ncbi.nlm.nih.gov/34261635/
268. Spontaneous HIT syndrome: knee replacement, infection, and parallels with vaccine-
induced immune thrombotic thrombocytopenia: https://pubmed.ncbi.nlm.nih.gov/34144250/
269. Deep venous thrombosis (DVT) occurring shortly after second dose of SARS-CoV-2
mRNA vaccine: https://pubmed.ncbi.nlm.nih.gov/33687691/
274. Acute cerebral venous thrombosis and pulmonary artery embolism associated with the
COVID-19 vaccine: https://pubmed.ncbi.nlm.nih.gov/34247246/.
282. Intracerebral hemorrhage twelve days after vaccination with ChAdOx1 nCoV-
19: https://pubmed.ncbi.nlm.nih.gov/34477089/
285. Comparison of adverse drug reactions among four COVID-19 vaccines in Europe using
the EudraVigilance database: Thrombosis in unusual
sites: https://pubmed.ncbi.nlm.nih.gov/34375510/
293. Sensory Guillain-Barré syndrome following ChAdOx1 nCov-19 vaccine: report of two
cases and review of the literature: https://pubmed.ncbi.nlm.nih.gov/34416410/.
295. Reactivation of Vogt-Koyanagi-Harada disease under control for more than 6 years, after
anti-SARS-CoV-2 vaccination: https://pubmed.ncbi.nlm.nih.gov/34224024/.
298. Fatal systemic capillary leak syndrome after SARS-COV-2 vaccination in a patient with
multiple myeloma: https://pubmed.ncbi.nlm.nih.gov/34459725/
299. Polyarthralgia and myalgia syndrome after vaccination with ChAdOx1 nCOV-
19: https://pubmed.ncbi.nlm.nih.gov/34463066/
300. Three cases of subacute thyroiditis after SARS-CoV-2 vaccination: post-vaccination ASIA
syndrome: https://pubmed.ncbi.nlm.nih.gov/34043800/.
301. Facial diplegia: a rare and atypical variant of Guillain-Barré syndrome and the
Ad26.COV2.S vaccine: https://pubmed.ncbi.nlm.nih.gov/34447646/
302. Association between ChAdOx1 nCoV-19 vaccination and bleeding episodes: large
population-based cohort study: https://pubmed.ncbi.nlm.nih.gov/34479760/.
304. Adverse effects reported after COVID-19 vaccination in a tertiary care hospital, centered
on cerebral venous sinus thrombosis (CVST): https://pubmed.ncbi.nlm.nih.gov/34092166/
305. Induction and exacerbation of subacute cutaneous lupus erythematosus erythematosus
after mRNA- or adenoviral vector-based SARS-CoV-2
vaccination: https://pubmed.ncbi.nlm.nih.gov/34291477/
306. Petechiae and peeling of fingers after immunization with BTN162b2 messenger RNA
(mRNA)-based COVID-19 vaccine: https://pubmed.ncbi.nlm.nih.gov/34513435/
313. Acute relapse and impaired immunization after COVID-19 vaccination in a patient with
multiple sclerosis treated with rituximab: https://pubmed.ncbi.nlm.nih.gov/34015240/
314. Widespread fixed bullous drug eruption after vaccination with ChAdOx1 nCoV-
19: https://pubmed.ncbi.nlm.nih.gov/34482558/
319. Systemic capillary extravasation syndrome following vaccination with ChAdOx1 nCOV-19
(Oxford-AstraZeneca): https://pubmed.ncbi.nlm.nih.gov/34362727/
323. Transient cardiac injury in adolescents receiving the BNT162b2 mRNA COVID-19
vaccine: https://pubmed.ncbi.nlm.nih.gov/34077949/
326. Lymphohistocytic myocarditis after vaccination with the COVID-19 viral vector
Ad26.COV2.S: https://pubmed.ncbi.nlm.nih.gov/34514078/
328. IgA vasculitis in adult patient after vaccination with ChadOx1 nCoV-
19: https://pubmed.ncbi.nlm.nih.gov/34509658/
329. A case of leukocytoclastic vasculitis after vaccination with a SARS-CoV2 vaccine: case
report: https://pubmed.ncbi.nlm.nih.gov/34196469/.
330. Onset / outbreak of psoriasis after Corona virus ChAdOx1 nCoV-19 vaccine (Oxford-
AstraZeneca / Covishield): report of two cases: https://pubmed.ncbi.nlm.nih.gov/34350668/
334. Report of the International Cerebral Venous Thrombosis Consortium on cerebral venous
thrombosis after SARS-CoV-2 vaccination: https://pubmed.ncbi.nlm.nih.gov/34462996/
336. COVID-19: lessons from the Norwegian tragedy should be taken into account in planning
for vaccine launch in less developed/developing
countries: https://pubmed.ncbi.nlm.nih.gov/34435142/
340. Vesiculobullous cutaneous reactions induced by COVID-19 mRNA vaccine: report of four
cases and review of the literature: https://pubmed.ncbi.nlm.nih.gov/34236711/
344. Rare cutaneous adverse effects of COVID-19 vaccines: a case series and review of the
literature: https://pubmed.ncbi.nlm.nih.gov/34363637/
351. Immune thrombocytopenic purpura and acute liver injury after COVID-19
vaccination: https://casereports.bmj.com/content/14/7/e242678.
353. Petechial rash associated with CoronaVac vaccination: first report of cutaneous side
effects before phase 3 results: https://ejhp.bmj.com/content/early/2021/05/23/ejhpharm-
2021-002794
354. COVID-19 vaccines induce severe hemolysis in paroxysmal nocturnal
hemoglobinuria: https://ashpublications.org/blood/article/137/26/3670/475905/COVID-19-
vaccines-induce-severe-hemolysis-in
356. Cerebral venous sinus thrombosis after COVID-19 vaccination : Neurological and
radiological management: https://pubmed.ncbi.nlm.nih.gov/34327553/.
358. Cerebral venous sinus thrombosis and thrombocytopenia after COVID-19 vaccination:
report of two cases in the United Kingdom: https://pubmed.ncbi.nlm.nih.gov/33857630/.
366. Cerebral venous sinus thrombosis in the U.S. population, After SARS-CoV-2 vaccination
with adenovirus and after COVID-19: https://pubmed.ncbi.nlm.nih.gov/34116145/
367. Cerebral venous thrombosis after COVID-19 vaccination: is the risk of thrombosis
increased by intravascular administration of the
vaccine: https://pubmed.ncbi.nlm.nih.gov/34286453/.
368. Central venous sinus thrombosis with subarachnoid hemorrhage after COVID-19 mRNA
vaccination: are these reports merely coincidental: https://pubmed.ncbi.nlm.nih.gov/34478433/
369. Cerebral venous sinus thrombosis after ChAdOx1 nCov-19 vaccination with a misleading
first brain MRI: https://pubmed.ncbi.nlm.nih.gov/34244448/
370. Early results of bivalirudin treatment for thrombotic thrombocytopenia and cerebral
venous sinus thrombosis after vaccination with
Ad26.COV2.S: https://pubmed.ncbi.nlm.nih.gov/34226070/
372. Cerebral venous sinus thrombosis 2 weeks after the first dose of SARS-CoV-2 mRNA
vaccine: https://pubmed.ncbi.nlm.nih.gov/34101024/.
376. Adverse effects reported after COVID-19 vaccination in a tertiary care hospital, focus on
cerebral venous sinus thrombosis (CVST): https://pubmed.ncbi.nlm.nih.gov/34092166/
377. Cerebral venous sinus thrombosis following vaccination against SARS-CoV-2: an analysis
of cases reported to the European Medicines
Agency: https://pubmed.ncbi.nlm.nih.gov/34293217/
378. A rare case of a middle-age Asian male with cerebral venous thrombosis after COVID-19
AstraZeneca vaccination: https://pubmed.ncbi.nlm.nih.gov/34274191/
379. Cerebral venous sinus thrombosis negative for anti-PF4 antibody without
thrombocytopenia after immunization with COVID-19 vaccine in a non-comorbid elderly Indian
male treated with conventional heparin-warfarin-based
anticoagulation: https://pubmed.ncbi.nlm.nih.gov/34186376/
382. S. case reports of cerebral venous sinus thrombosis with thrombocytopenia after
vaccination with Ad26.COV2.S, March 2-April 21,
2021: https://pubmed.ncbi.nlm.nih.gov/33929487/.
383. Malignant cerebral infarction after vaccination with ChAdOx1 nCov-19: a catastrophic
variant of vaccine-induced immune-mediated thrombotic
thrombocytopenia: https://pubmed.ncbi.nlm.nih.gov/34341358/
389. Massive cerebral venous thrombosis and venous basin infarction as late complications
of COVID-19: a case report: https://pubmed.ncbi.nlm.nih.gov/34373991/
390. Australian and New Zealand approach to the diagnosis and treatment of vaccine-
induced immune thrombosis and immune
thrombocytopenia: https://pubmed.ncbi.nlm.nih.gov/34490632/
392. Acute transverse myelitis (ATM): clinical review of 43 patients with COVID-19-associated
ATM and 3 serious adverse events of post-vaccination ATM with ChAdOx1 nCoV-19 (AZD1222)
vaccine: https://pubmed.ncbi.nlm.nih.gov/33981305/.
393. A case of acute demyelinating polyradiculoneuropathy with bilateral facial palsy after
ChAdOx1 nCoV-19 vaccine:. https://pubmed.ncbi.nlm.nih.gov/34272622/
394. Thrombocytopenia with acute ischemic stroke and hemorrhage in a patient recently
vaccinated with an adenoviral vector-based COVID-19
vaccine:. https://pubmed.ncbi.nlm.nih.gov/33877737/
395. Predicted and observed incidence of thromboembolic events among Koreans vaccinated
with the ChAdOx1 nCoV-19 vaccine: https://pubmed.ncbi.nlm.nih.gov/34254476/
396. First dose of ChAdOx1 and BNT162b2 COVID-19 vaccines and thrombocytopenic,
thromboembolic, and hemorrhagic events in
Scotland: https://pubmed.ncbi.nlm.nih.gov/34108714/
397. ChAdOx1 nCoV-19 vaccine-associated thrombocytopenia: three cases of immune
thrombocytopenia after 107,720 doses of ChAdOx1 vaccination in
Thailand: https://pubmed.ncbi.nlm.nih.gov/34483267/.
398. Pulmonary embolism, transient ischemic attack, and thrombocytopenia after Johnson &
Johnson COVID-19 vaccine: https://pubmed.ncbi.nlm.nih.gov/34261635/
400. Large hemorrhagic stroke after vaccination against ChAdOx1 nCoV-19: a case
report: https://pubmed.ncbi.nlm.nih.gov/34273119/
401. Polyarthralgia and myalgia syndrome after vaccination with ChAdOx1 nCOV-
19: https://pubmed.ncbi.nlm.nih.gov/34463066/
402. A rare case of thrombosis and thrombocytopenia of the superior ophthalmic vein after
ChAdOx1 nCoV-19 vaccination against SARS-CoV-
2: https://pubmed.ncbi.nlm.nih.gov/34276917/
403. Thrombosis and severe acute respiratory syndrome Coronavirus 2 vaccines: vaccine-
induced immune thrombotic thrombocytopenia: https://pubmed.ncbi.nlm.nih.gov/34237213/.
405. Limb ischemia and pulmonary artery thrombosis after ChAdOx1 nCoV-19 vaccine
(Oxford-AstraZeneca): a case of vaccine-induced immune thrombotic
thrombocytopenia: https://pubmed.ncbi.nlm.nih.gov/33990339/.
406. Association between ChAdOx1 nCoV-19 vaccination and bleeding episodes: large
population-based cohort study: https://pubmed.ncbi.nlm.nih.gov/34479760/.
408. Venous thromboembolism and mild thrombocytopenia after vaccination with ChAdOx1
nCoV-19: https://pubmed.ncbi.nlm.nih.gov/34384129/
421. Intravenous injection of coronavirus disease 2019 (COVID-19) mRNA vaccine can induce
acute myopericarditis in a mouse model: https://t.co/j0IEM8cMXI
422. A report of myocarditis adverse events in the U.S. Vaccine Adverse Event Reporting
System. (VAERS) in association with COVID-19 injectable
biologics: https://pubmed.ncbi.nlm.nih.gov/34601006/
423. This study concludes that: “The vaccine was associated with an excess risk of
myocarditis (1 to 5 events per 100,000 persons). The risk of this potentially serious adverse
event and of many other serious adverse events increased substantially after SARS-CoV-2
infection”: https://www.nejm.org/doi/full/10.1056/NEJMoa2110475
426. Immune-mediated hepatitis with the Moderna vaccine is no longer a coincidence but
confirmed: https://www.sciencedirect.com/science/article/pii/S0168827821020936
427. Extensive investigations revealed consistent pathophysiologic alterations after
vaccination with COVID-19 vaccines: https://www.nature.com/articles/s41421-021-00329-3
428. Lobar hemorrhage with ventricular rupture shortly after the first dose of an mRNA-
based SARS-CoV-2 vaccine: https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8553377/
429. Mrna COVID vaccines dramatically increase endothelial inflammatory markers and risk
of Acute Coronary Syndrome as measured by PULS cardiac testing: a
caution: https://www.ahajournals.org/doi/10.1161/circ.144.suppl_1.10712
430. ChAdOx1 interacts with CAR and PF4 with implications for thrombosis with
thrombocytopenia syndrome:https://www.science.org/doi/10.1126/sciadv.abl8213
435. Treatment of acute ischemic stroke associated with ChAdOx1 nCoV-19 vaccine-induced
immune thrombotic thrombocytopenia: https://pubmed.ncbi.nlm.nih.gov/34461442/
438. Cerebral venous vein/venous sinus thrombosis with thrombocytopenia syndrome after
COVID-19 vaccination: https://pubmed.ncbi.nlm.nih.gov/34373413/
440. Hematuria, a generalized petechial rash and headaches after Oxford AstraZeneca
ChAdOx1 nCoV-19 vaccination: https://pubmed.ncbi.nlm.nih.gov/34620638/
441. Myocardial infarction and azygos vein thrombosis after vaccination with ChAdOx1 nCoV-
19 in a hemodialysis patient: https://pubmed.ncbi.nlm.nih.gov/34650896/
446. Rare case of COVID-19 vaccine-associated intracranial hemorrhage with venous sinus
thrombosis: https://pubmed.ncbi.nlm.nih.gov/34556531/.
447. Delayed headache after COVID-19 vaccination: a warning sign for vaccine-induced
cerebral venous thrombosis: https://pubmed.ncbi.nlm.nih.gov/34535076/.
452. Endovascular treatment for vaccine-induced cerebral venous sinus thrombosis and
thrombocytopenia after vaccination with ChAdOx1 nCoV-19: report of three
cases: https://pubmed.ncbi.nlm.nih.gov/34782400/
453. Cardiovascular, neurological, and pulmonary events after vaccination with BNT162b2,
ChAdOx1 nCoV-19, and Ad26.COV2.S vaccines: an analysis of European
data: https://pubmed.ncbi.nlm.nih.gov/34710832/
454. Cerebral venous thrombosis developing after vaccination. COVID-19: VITT, VATT, TTS
and more: https://pubmed.ncbi.nlm.nih.gov/34695859/
457. Multiple sites of arterial thrombosis in a 35-year-old patient after vaccination with
ChAdOx1 (AstraZeneca), which required emergency femoral and carotid surgical
thrombectomy: https://pubmed.ncbi.nlm.nih.gov/34644642/
460. Thrombotic events after COVID-19 vaccination in over 50 years of age: results of a
population-based study in Italy: https://pubmed.ncbi.nlm.nih.gov/34835237/
462. Age- and sex-specific incidence of cerebral venous sinus thrombosis associated with
Ad26.COV2.S COVID-19 vaccination: https://pubmed.ncbi.nlm.nih.gov/34724036/.
463. Genital necrosis with cutaneous thrombosis following vaccination with COVID-19
mRNA: https://pubmed.ncbi.nlm.nih.gov/34839563/
470. Thrombosis with thrombocytopenia syndrome (TTS) after vaccination with AstraZeneca
ChAdOx1 nCoV-19 (AZD1222) COVID-19: a risk-benefit analysis for persons <60% risk-benefit
analysis for people <60 years in Australia: https://pubmed.ncbi.nlm.nih.gov/34272095/
472. Characteristics and outcomes of patients with cerebral venous sinus thrombosis in
thrombotic immune thrombocytopenia induced by SARS-CoV-2
vaccine: https://jamanetwork.com/journals/jamaneurology/fullarticle/2784622
473. Case study of thrombosis and thrombocytopenia syndrome after administration of the
AstraZeneca COVID-19 vaccine: https://pubmed.ncbi.nlm.nih.gov/34781321/
474. Thrombosis with Thrombocytopenia Syndrome Associated with COVID-19
Vaccines: https://pubmed.ncbi.nlm.nih.gov/34062319/
475. Cerebral venous sinus thrombosis following vaccination with ChAdOx1: the first case of
definite thrombosis with thrombocytopenia syndrome in
India: https://pubmed.ncbi.nlm.nih.gov/34706921/
477. Case report of immune thrombocytopenia after vaccination with ChAdOx1 nCoV-
19: https://pubmed.ncbi.nlm.nih.gov/34751013/.
479. Concerns for adverse effects of thrombocytopenia and thrombosis after adenovirus-
vectored COVID-19 vaccination: https://pubmed.ncbi.nlm.nih.gov/34541935/
481. Cerebral venous sinus thrombosis after COVID-19 vaccination: neurologic and radiologic
management: https://pubmed.ncbi.nlm.nih.gov/34327553/.
482. Thrombocytopenia with acute ischemic stroke and hemorrhage in a patient recently
vaccinated with an adenoviral vector-based COVID-19
vaccine: https://pubmed.ncbi.nlm.nih.gov/33877737/
484. Minimal change disease with severe acute kidney injury after Oxford-AstraZeneca
COVID-19 vaccine: case report: https://pubmed.ncbi.nlm.nih.gov/34242687/.
485. Case report: cerebral sinus vein thrombosis in two patients with AstraZeneca SARS-CoV-
2 vaccine: https://pubmed.ncbi.nlm.nih.gov/34609603/
486. Case report: Pityriasis rosea-like rash after vaccination with COVID-
19: https://pubmed.ncbi.nlm.nih.gov/34557507/
487. Extensive longitudinal transverse myelitis after ChAdOx1 nCOV-19 vaccine: case
report: https://pubmed.ncbi.nlm.nih.gov/34641797/.
494. Cerebral venous sinus thrombosis and thrombotic events after vector-based COVID-19
vaccines: systematic review and meta-analysis: https://pubmed.ncbi.nlm.nih.gov/34610990/.
497. Prevalence of serious adverse events among health care professionals after receiving
the first dose of ChAdOx1 nCoV-19 coronavirus vaccine (Covishield) in Togo, March
2021: https://pubmed.ncbi.nlm.nih.gov/34819146/.
499. Recurrence of alopecia areata after covid-19 vaccination: a report of three cases in
Italy: https://pubmed.ncbi.nlm.nih.gov/34741583/
500. Shingles-like skin lesion after vaccination with AstraZeneca for COVID-19: a case
report: https://pubmed.ncbi.nlm.nih.gov/34631069/
504. Abdominal pain and bilateral adrenal hemorrhage from immune thrombotic
thrombocytopenia induced by COVID-19 vaccine: https://pubmed.ncbi.nlm.nih.gov/34546343/
505. Longitudinally extensive cervical myelitis after vaccination with inactivated virus based
COVID-19 vaccine: https://pubmed.ncbi.nlm.nih.gov/34849183/
506. Induction of cutaneous leukocytoclastic vasculitis after ChAdOx1 nCoV-19
vaccine: https://pubmed.ncbi.nlm.nih.gov/34853744/.
507. A case of toxic epidermal necrolysis after vaccination with ChAdOx1 nCoV-19
(AZD1222): https://pubmed.ncbi.nlm.nih.gov/34751429/.
514. Cutaneous lymphocytic vasculitis after administration of the second dose of AZD1222
(Oxford-AstraZeneca) Severe acute respiratory syndrome Coronavirus 2 vaccine: chance or
causality: https://pubmed.ncbi.nlm.nih.gov/34726187/.
517. Cutaneous adverse reactions of 35,229 doses of COVID-19 Sinovac and AstraZeneca
vaccine COVID-19: a prospective cohort study in health care
workers: https://pubmed.ncbi.nlm.nih.gov/34661934/
518. Comments on thrombosis after vaccination: spike protein leader sequence could be
responsible for thrombosis and antibody-mediated
thrombocytopenia: https://pubmed.ncbi.nlm.nih.gov/34788138
520. Severe immune thrombocytopenia following COVID-19 vaccination: report of four cases
and review of the literature: https://pubmed.ncbi.nlm.nih.gov/34653943/.
527. An unusual presentation of acute deep vein thrombosis after Modern COVID-19 vaccine:
case report: https://pubmed.ncbi.nlm.nih.gov/34790811/
532. Cerebral venous sinus thrombosis, pulmonary embolism, and thrombocytopenia after
COVID-19 vaccination in a Taiwanese man: a case report and review of the
literature: https://pubmed.ncbi.nlm.nih.gov/34630307/
540. Cerebral venous sinus thrombosis following vaccination with Pfizer-BioNTech COVID-19
(BNT162b2): https://pubmed.ncbi.nlm.nih.gov/34595867/
545. Potential risk of thrombotic events after COVID-19 vaccination with Oxford-AstraZeneca
in women receiving estrogen: https://pubmed.ncbi.nlm.nih.gov/34734086/
547. Adenovirus interactions with platelets and coagulation and vaccine-induced immune
thrombotic thrombocytopenia syndrome: https://pubmed.ncbi.nlm.nih.gov/34407607/
549. Unusual site of deep vein thrombosis after vaccination against coronavirus mRNA-2019
coronavirus disease (COVID-19): https://pubmed.ncbi.nlm.nih.gov/34840204/
551. Coagulopathies after SARS-CoV-2 vaccination may derive from a combined effect of
SARS-CoV-2 spike protein and adenovirus vector-activated signaling
pathways: https://pubmed.ncbi.nlm.nih.gov/34639132/
552. Isolated pulmonary embolism after COVID vaccination: 2 case reports and a review of
acute pulmonary embolism complications and follow-
up: https://pubmed.ncbi.nlm.nih.gov/34804412/
553. Central retinal vein occlusion after vaccination with SARS-CoV-2 mRNA: case
report: https://pubmed.ncbi.nlm.nih.gov/34571653/.
557. Severe autoimmune hemolytic autoimmune anemia after receiving SARS-CoV-2 mRNA
vaccine: https://pubmed.ncbi.nlm.nih.gov/34549821/
561. Myocarditis after 2019 coronavirus disease mRNA vaccine: a case series and
determination of incidence rate: https://academic.oup.com/cid/advance-
article/doi/10.1093/cid/ciab926/6420408
562. Myocarditis and pericarditis after COVID-19 vaccination: inequalities in age and vaccine
types: https://www.mdpi.com/2075-4426/11/11/1106
564. Shedding light on post-vaccination myocarditis and pericarditis in COVID-19 and non-
COVID-19 vaccine recipients: https://pubmed.ncbi.nlm.nih.gov/34696294/
574. Association of myocarditis with COVID-19 messenger RNA BNT162b2 vaccine in a case
series of children: https://jamanetwork.com/journals/jamacardiology/fullarticle/2783052
576. STEMI mimicry: focal myocarditis in an adolescent patient after COVID-19 mRNA
vaccination:. https://pubmed.ncbi.nlm.nih.gov/34756746/
577. Myocarditis and pericarditis in association with COVID-19 mRNA vaccination: cases from
a regional pharmacovigilance
center: https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8587334/
582. Myocarditis findings on cardiac magnetic resonance imaging after vaccination with
COVID-19 mRNA in adolescents:. https://pubmed.ncbi.nlm.nih.gov/34704459/
586. Case report: probable myocarditis after Covid-19 mRNA vaccine in a patient with
arrhythmogenic left ventricular cardiomyopathy: https://pubmed.ncbi.nlm.nih.gov/34712717/.
593. Myocarditis associated with COVID-19 vaccination: echocardiographic, cardiac CT, and
MRI findings:. https://pubmed.ncbi.nlm.nih.gov/34428917/.
595. Myocarditis and pericarditis in adolescents after first and second doses of COVID-19
mRNA vaccines:. https://academic.oup.com/ehjqcco/advance-
article/doi/10.1093/ehjqcco/qcab090/64 42104.
599. Acute myocardial injury after COVID-19 vaccination: a case report and review of current
evidence from the vaccine adverse event reporting system
database: https://pubmed.ncbi.nlm.nih.gov/34219532/
600. Acute myocarditis associated with COVID-19 vaccination: report of a
case: https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8639400/
601. Myocarditis following vaccination with COVID-19 messenger RNA: a Japanese case
series: https://pubmed.ncbi.nlm.nih.gov/34840235/.
603. Acute myocarditis after a second dose of COVID-19 mRNA vaccine: report of two
cases: https://www.clinicalimaging.org/article/S0899-7071(21)00265-5/fulltext.
606. Myocarditis after 2019 coronavirus disease mRNA vaccine: a case series and incidence
rate determination: https://academic.oup.com/cid/advance-
article/doi/10.1093/cid/ciab926/6420408.
607. Myocarditis and pericarditis after COVID-19 vaccination: inequalities in age and vaccine
types: https://www.mdpi.com/2075-4426/11/11/1106
609. Shedding light on post-vaccination myocarditis and pericarditis in COVID-19 and non-
COVID-19 vaccine recipients: https://pubmed.ncbi.nlm.nih.gov/34696294/
611. Three cases of acute venous thromboembolism in women after coronavirus 2019
vaccination: https://pubmed.ncbi.nlm.nih.gov/34352418/
612. Clinical and biological features of cerebral venous sinus thrombosis after vaccination
with ChAdOx1 nCov-19; https://jnnp.bmj.com/content/early/2021/09/29/jnnp-2021-327340.
613. COV2-S vaccination may reveal hereditary thrombophilia: massive cerebral venous sinus
thrombosis in a young man with normal platelet
count: https://pubmed.ncbi.nlm.nih.gov/34632750/
616. Inflammation and platelet activation after COVID-19 vaccines: possible mechanisms
behind vaccine-induced immune thrombocytopenia and
thrombosis: https://pubmed.ncbi.nlm.nih.gov/34887867/.
619. Occurrence of splenic infarction due to arterial thrombosis after vaccination with
COVID-19: https://pubmed.ncbi.nlm.nih.gov/34876440/
620. Deep venous thrombosis more than two weeks after COVID-19
vaccination: https://pubmed.ncbi.nlm.nih.gov/33928773/
621. Case report: Take a second look: Cerebral venous thrombosis related to Covid-19
vaccination and thrombotic thrombocytopenia
syndrome: https://pubmed.ncbi.nlm.nih.gov/34880826/
623. Change in blood viscosity after COVID-19 vaccination: estimation for persons with
underlying metabolic syndrome: https://pubmed.ncbi.nlm.nih.gov/34868465/
624. Management of a patient with a rare congenital limb malformation syndrome after
SARS-CoV-2 vaccine-induced thrombosis and thrombocytopenia
(VITT): https://pubmed.ncbi.nlm.nih.gov/34097311/
625. Bilateral thalamic stroke: a case of COVID-19 (VITT) vaccine-induced immune thrombotic
thrombocytopenia or a coincidence due to underlying risk
factors: https://pubmed.ncbi.nlm.nih.gov/34820232/.
627. Incidence of acute ischemic stroke after coronavirus vaccination in Indonesia: case
series: https://pubmed.ncbi.nlm.nih.gov/34579636/
631. Squamous cell carcinoma of the lung with hemoptysis following vaccination with
tozinameran (BNT162b2, Pfizer-BioNTech): https://pubmed.ncbi.nlm.nih.gov/34612003/
634. Cardiovascular magnetic resonance findings in young adult patients with acute
myocarditis after COVID-19 mRNA vaccination: a case
series: https://pubmed.ncbi.nlm.nih.gov/34496880/
638. Acute myocarditis after vaccination with COVID-19 mRNA in adults aged 18 years or
older: https://pubmed.ncbi.nlm.nih.gov/34605853/
639. Recurrence of acute myocarditis temporally associated with receipt of the 2019
coronavirus mRNA disease vaccine (COVID-19) in an adolescent
male: https://pubmed.ncbi.nlm.nih.gov/34166671/
640. Young male with myocarditis after mRNA-1273 coronavirus disease-2019 (COVID-19)
mRNA vaccination: https://pubmed.ncbi.nlm.nih.gov/34744118/
642. Ga-DOTATOC digital PET images of inflammatory cell infiltrates in myocarditis after
vaccination with COVID-19: https://pubmed.ncbi.nlm.nih.gov/34746968/
643. Occurrence of acute infarct-like myocarditis after vaccination with COVID-19: just an
accidental coincidence or rather a vaccination-associated autoimmune
myocarditis?”: https://pubmed.ncbi.nlm.nih.gov/34333695/.
644. Self-limited myocarditis presenting with chest pain and ST-segment elevation in
adolescents after vaccination with BNT162b2 mRNA
vaccine: https://pubmed.ncbi.nlm.nih.gov/34180390/
645. Myocarditis Following Immunization with COVID-19 mRNA Vaccines in Members of the
U.S. Military: https://pubmed.ncbi.nlm.nih.gov/34185045/
649. Chest pain with abnormal electrocardiogram redevelopment after injection of COVID-19
vaccine manufactured by Moderna: https://pubmed.ncbi.nlm.nih.gov/34866106/
650. Biopsy-proven lymphocytic myocarditis after first vaccination with COVID-19 mRNA in a
40-year-old man: case report: https://pubmed.ncbi.nlm.nih.gov/34487236/
651. Multimodality imaging and histopathology in a young man presenting with fulminant
lymphocytic myocarditis and cardiogenic shock after vaccination with mRNA-
1273: https://pubmed.ncbi.nlm.nih.gov/34848416/
652. Report of a case of myopericarditis after vaccination with BNT162b2 COVID-19 mRNA in
a young Korean male: https://pubmed.ncbi.nlm.nih.gov/34636504/
653. Acute myocarditis after Comirnaty vaccination in a healthy male with previous SARS-
CoV-2 infection: https://pubmed.ncbi.nlm.nih.gov/34367386/
654. Acute myocarditis in a young adult two days after vaccination with
Pfizer: https://pubmed.ncbi.nlm.nih.gov/34709227/
655. Case report: acute fulminant myocarditis and cardiogenic shock after messenger RNA
coronavirus vaccination in 2019 requiring extracorporeal cardiopulmonary
resuscitation: https://pubmed.ncbi.nlm.nih.gov/34778411/
657. A series of patients with myocarditis after vaccination against SARS-CoV-2 with mRNA-
1279 and BNT162b2: https://pubmed.ncbi.nlm.nih.gov/34246585/
658. Myopericarditis after Pfizer messenger ribonucleic acid coronavirus coronavirus disease
vaccine in adolescents: https://pubmed.ncbi.nlm.nih.gov/34228985/
660. Acute myocarditis defined after vaccination with 2019 mRNA of coronavirus
disease: https://pubmed.ncbi.nlm.nih.gov/34866122/
661. Biventricular systolic dysfunction in acute myocarditis after SARS-CoV-2 mRNA-1273
vaccination: https://pubmed.ncbi.nlm.nih.gov/34601566/
664. Association of myocarditis with COVID-19 messenger RNA BNT162b2 vaccine COVID-19
in a case series of children: https://pubmed.ncbi.nlm.nih.gov/34374740/
669. Guillain-Barré syndrome after the first dose of Pfizer-BioNTech COVID-19 vaccine: case
report and review of reported cases: https://pubmed.ncbi.nlm.nih.gov/34796417/.
680. Guillain-Barre syndrome presenting with facial diplegia following vaccination with
COVID-19 in two patients: https://pubmed.ncbi.nlm.nih.gov/34649856/
684. Guillain-Barre syndrome after the first dose of COVID-19 vaccination: case
report; https://pubmed.ncbi.nlm.nih.gov/34779385/.
687. Bilateral facial weakness with a variant of paresthesia of Guillain-Barre syndrome after
Vaxzevria COVID-19 vaccine: https://pubmed.ncbi.nlm.nih.gov/34261746/
688. Guillain-Barre syndrome after the first injection of ChAdOx1 nCoV-19 vaccine: first
report: https://pubmed.ncbi.nlm.nih.gov/34217513/.
694. Guillain-Barré syndrome in an Australian state using mRNA and adenovirus-vector SARS-
CoV-2 vaccines: https://onlinelibrary.wiley.com/doi/10.1002/ana.26218.
695. Acute transverse myelitis after SARS-CoV-2 vaccination: case report and review of the
literature: https://pubmed.ncbi.nlm.nih.gov/34482455/.
697. Guillian-Barre syndrome with axonal variant temporally associated with Modern SARS-
CoV-2 mRNA-based vaccine: https://pubmed.ncbi.nlm.nih.gov/34722067/
698. Guillain-Barre syndrome after the first dose of SARS-CoV-2 vaccine: a temporary
occurrence, not a causal association: https://pubmed.ncbi.nlm.nih.gov/33968610/
699. SARS-CoV-2 vaccines can be complicated not only by Guillain-Barré syndrome but also
by distal small fiber neuropathy: https://pubmed.ncbi.nlm.nih.gov/34525410/
700. Clinical variant of Guillain-Barré syndrome with prominent facial diplegia after
AstraZeneca 2019 coronavirus disease vaccine: https://pubmed.ncbi.nlm.nih.gov/34808658/
701. Adverse event reporting and risk of Bell’s palsy after COVID-19
vaccination: https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(21)00646-
0/fulltext.
703. Left Bell’s palsy after the first dose of mRNA-1273 SARS-CoV-2 vaccine: case
report: https://pubmed.ncbi.nlm.nih.gov/34763263/.
704. Bell’s palsy after inactivated vaccination with COVID-19 in a patient with a history of
recurrent Bell’s palsy: case report: https://pubmed.ncbi.nlm.nih.gov/34621891/
705. Neurological complications after the first dose of COVID-19 vaccines and SARS-CoV-2
infection: https://pubmed.ncbi.nlm.nih.gov/34697502/
706. Type I interferons as a potential mechanism linking COVID-19 mRNA vaccines with Bell’s
palsy: https://pubmed.ncbi.nlm.nih.gov/33858693/
710. Post COVID-19 transverse myelitis; a case report with review of the
literature: https://pubmed.ncbi.nlm.nih.gov/34457267/.
711. Beware of neuromyelitis optica spectrum disorder after vaccination with inactivated
virus for COVID-19: https://pubmed.ncbi.nlm.nih.gov/34189662/
712. Neuromyelitis optica in a healthy woman after vaccination against severe acute
respiratory syndrome coronavirus 2 mRNA-1273: https://pubmed.ncbi.nlm.nih.gov/34660149/
713. Acute bilateral bilateral optic neuritis/chiasm with longitudinal extensive transverse
myelitis in long-standing stable multiple sclerosis after vector-based vaccination against SARS-
CoV-2: https://pubmed.ncbi.nlm.nih.gov/34131771/
714. A case series of acute pericarditis after vaccination with COVID-19 in the context of
recent reports from Europe and the United States: https://pubmed.ncbi.nlm.nih.gov/34635376/
715. Acute pericarditis and cardiac tamponade after vaccination with Covid-
19: https://pubmed.ncbi.nlm.nih.gov/34749492/
716. Myocarditis and pericarditis in adolescents after the first and second doses of COVID-19
mRNA vaccines: https://pubmed.ncbi.nlm.nih.gov/34849667/
724. Miller-Fisher syndrome and Guillain-Barré syndrome overlap syndrome in a patient after
Oxford-AstraZeneca SARS-CoV-2 vaccination: https://pubmed.ncbi.nlm.nih.gov/34848426/.
727. Acute kidney injury with macroscopic hematuria and IgA nephropathy after COVID-19
vaccination: https://pubmed.ncbi.nlm.nih.gov/34352309/
731. Case report: anti-neutrophil cytoplasmic antibody-associated vasculitis with acute renal
failure and pulmonary hemorrhage can occur after COVID-19
vaccination: https://pubmed.ncbi.nlm.nih.gov/34859017/
736. Lobar hemorrhage with ventricular rupture shortly after the first dose of a SARS-CoV-2
mRNA-based SARS-CoV-2 vaccine: https://pubmed.ncbi.nlm.nih.gov/34729467/.
737. A case of outbreak of macroscopic hematuria and IgA nephropathy after SARS-CoV-2
vaccination: https://pubmed.ncbi.nlm.nih.gov/33932458/
738. Acral hemorrhage after administration of the second dose of SARS-CoV-2 vaccine. A
post-vaccination reaction: https://pubmed.ncbi.nlm.nih.gov/34092400/742.
740. Gross hematuria after severe acute respiratory syndrome coronavirus 2 vaccination in 2
patients with IgA nephropathy: https://pubmed.ncbi.nlm.nih.gov/33771584/
742. COVID-19 vaccine and death: causality algorithm according to the WHO eligibility
diagnosis: https://pubmed.ncbi.nlm.nih.gov/34073536/
743. Bell’s palsy after vaccination with mRNA (BNT162b2) and inactivated (CoronaVac) SARS-
CoV-2 vaccines: a case series and a nested case-control
study: https://pubmed.ncbi.nlm.nih.gov/34411532/
746. Anaphylaxis induced by CoronaVac COVID-19 vaccine: clinical features and results of
revaccination: https://pubmed.ncbi.nlm.nih.gov/34675550/.
748. Association of self-reported history of high-risk allergy with allergy symptoms after
COVID-19 vaccination: https://pubmed.ncbi.nlm.nih.gov/34698847/
750. Allergic reactions, including anaphylaxis, after receiving the first dose of Pfizer-BioNTech
COVID-19 vaccine – United States, December 14 to 23,
2020: https://pubmed.ncbi.nlm.nih.gov/33641264/
751. Allergic reactions, including anaphylaxis, after receiving the first dose of Modern COVID-
19 vaccine – United States, December 21, 2020 to January 10,
2021: https://pubmed.ncbi.nlm.nih.gov/33641268/
752. Prolonged anaphylaxis to Pfizer 2019 coronavirus disease vaccine: a case report and
mechanism of action: https://pubmed.ncbi.nlm.nih.gov/33834172/
754. Biphasic anaphylaxis after first dose of 2019 messenger RNA coronavirus disease vaccine
with positive polysorbate 80 skin test result: https://pubmed.ncbi.nlm.nih.gov/34343674/
759. Myocardial infarction, stroke, and pulmonary embolism after BNT162b2 mRNA COVID-
19 vaccine in persons aged 75 years or older: https://pubmed.ncbi.nlm.nih.gov/34807248/
771. Vasculitis and bursitis in [ 18 F] FDG-PET/CT after COVID-19 mRNA vaccine: post hoc
ergo propter hoc?; https://pubmed.ncbi.nlm.nih.gov/34495381/.
774. Case report: ANCA-associated vasculitis presenting with rhabdomyolysis and crescentic
Pauci-Inmune glomerulonephritis after vaccination with Pfizer-BioNTech COVID-19
mRNA: https://pubmed.ncbi.nlm.nih.gov/34659268/
783. Coronavirus disease vaccine 2019 (COVID-19) in systemic lupus erythematosus and
neutrophil anti-cytoplasmic antibody-associated
vasculitis: https://pubmed.ncbi.nlm.nih.gov/33928459/
785. Clinical and histopathologic spectrum of delayed adverse skin reactions after COVID-19
vaccination: https://pubmed.ncbi.nlm.nih.gov/34292611/.
786. First description of immune complex vasculitis after COVID-19 vaccination with
BNT162b2: case report: https://pubmed.ncbi.nlm.nih.gov/34530771/.
787. Nephrotic syndrome and vasculitis after SARS-CoV-2 vaccine: true association or
circumstantial: https://pubmed.ncbi.nlm.nih.gov/34245294/.
791. Henoch-Schönlein purpura following the first dose of COVID-19 viral vector vaccine: case
report: https://pubmed.ncbi.nlm.nih.gov/34696186/.
793. Acute retinal necrosis due to varicella zoster virus reactivation after vaccination with
BNT162b2 COVID-19 mRNA: https://pubmed.ncbi.nlm.nih.gov/34851795/.
794. A case of generalized Sweet’s syndrome with vasculitis triggered by recent vaccination
with COVID-19: https://pubmed.ncbi.nlm.nih.gov/34849386/
798. Recurrent herpes zoster after COVID-19 vaccination in patients with chronic urticaria on
cyclosporine treatment – A report of 3 cases: https://pubmed.ncbi.nlm.nih.gov/34510694/
801. Cutaneous small-vessel vasculitis after vaccination with a single dose of Janssen
Ad26.COV2.S: https://pubmed.ncbi.nlm.nih.gov/34337124/
812. Coronavirus disease vaccine 2019 mimics lymph node metastases in patients
undergoing skin cancer follow-up: a single-center
study: https://pubmed.ncbi.nlm.nih.gov/34280870/
814. Regional lymphadenopathy after COVID-19 vaccination: review of the literature and
considerations for patient management in breast cancer
care: https://pubmed.ncbi.nlm.nih.gov/34731748/
819. Biphasic anaphylaxis after exposure to the first dose of Pfizer-BioNTech COVID-19 mRNA
vaccine COVID-19: https://pubmed.ncbi.nlm.nih.gov/34050949/
820. Axillary adenopathy associated with COVID-19 vaccination: imaging findings and follow-
up recommendations in 23 women: https://pubmed.ncbi.nlm.nih.gov/33624520/
823. Thrombotic adverse events reported for Moderna, Pfizer, and Oxford-AstraZeneca
COVID-19 vaccines: comparison of occurrence and clinical outcomes in the EudraVigilance
database: https://pubmed.ncbi.nlm.nih.gov/34835256/
830. Incidence of axillary adenopathy on breast imaging after vaccination with COVID-
19: https://pubmed.ncbi.nlm.nih.gov/34292295/.
831. COVID-19 vaccination and lower cervical lymphadenopathy in two-week neck lump
clinic: a follow-up audit: https://pubmed.ncbi.nlm.nih.gov/33947605/.
832. Cervical lymphadenopathy after coronavirus disease vaccination 2019: clinical features
and implications for head and neck cancer
services: https://pubmed.ncbi.nlm.nih.gov/34526175/
836. New-onset nephrotic syndrome after Janssen COVID-19 vaccination: case report and
literature review: https://pubmed.ncbi.nlm.nih.gov/34342187/.
840. Systemic capillary extravasation syndrome after vaccination with ChAdOx1 nCOV-19
(Oxford-AstraZeneca): https://pubmed.ncbi.nlm.nih.gov/34362727/
841. Unilateral axillary lymphadenopathy related to COVID-19 vaccine: pattern on screening
breast MRI allowing benign evaluation: https://pubmed.ncbi.nlm.nih.gov/34325221/
842. Axillary lymphadenopathy in patients with recent Covid-19 vaccination: a new diagnostic
dilemma: https://pubmed.ncbi.nlm.nih.gov/34825530/.
843. Minimal change disease and acute kidney injury after Pfizer-BioNTech COVID-19
vaccine: https://pubmed.ncbi.nlm.nih.gov/34000278/
849. Biphasic anaphylaxis after exposure to the first dose of Pfizer-BioNTech COVID-19 mRNA
vaccine COVID-19: https://pubmed.ncbi.nlm.nih.gov/34050949/
850. Axillary adenopathy associated with COVID-19 vaccination: imaging findings and follow-
up recommendations in 23 women: https://pubmed.ncbi.nlm.nih.gov/33624520/
853. Thrombotic adverse events reported for Moderna, Pfizer, and Oxford-AstraZeneca
COVID-19 vaccines: comparison of occurrence and clinical outcomes in the EudraVigilance
database: https://pubmed.ncbi.nlm.nih.gov/34835256/
860. Incidence of axillary adenopathy on breast imaging after vaccination with COVID-
19: https://pubmed.ncbi.nlm.nih.gov/34292295/.
861. COVID-19 vaccination and lower cervical lymphadenopathy in two-week neck lump
clinic: a follow-up audit: https://pubmed.ncbi.nlm.nih.gov/33947605/.
862. Cervical lymphadenopathy after coronavirus disease vaccination 2019: clinical features
and implications for head and neck cancer
services: https://pubmed.ncbi.nlm.nih.gov/34526175/
866. New-onset nephrotic syndrome after Janssen COVID-19 vaccination: case report and
literature review: https://pubmed.ncbi.nlm.nih.gov/34342187/.
870. Systemic capillary extravasation syndrome after vaccination with ChAdOx1 nCOV-19
(Oxford-AstraZeneca): https://pubmed.ncbi.nlm.nih.gov/34362727/
872. Axillary lymphadenopathy in patients with recent Covid-19 vaccination: a new diagnostic
dilemma: https://pubmed.ncbi.nlm.nih.gov/34825530/.
873. Minimal change disease and acute kidney injury after Pfizer-BioNTech COVID-19
vaccine: https://pubmed.ncbi.nlm.nih.gov/34000278/
876. Abbate, A., Gavin, J., Madanchi, N., Kim, C., Shah, P. R., Klein, K., . . . Danielides, S.
(2021). Fulminant myocarditis and systemic hyperinflammation temporally associated with
BNT162b2 mRNA COVID-19 vaccination in two patients. Int J Cardiol, 340, 119-121.
doi:10.1016/j.ijcard.2021.08.018. https://www.ncbi.nlm.nih.gov/pubmed/34416319
877. Abu Mouch, S., Roguin, A., Hellou, E., Ishai, A., Shoshan, U., Mahamid, L., . . . Berar
Yanay, N. (2021). Myocarditis following COVID-19 mRNA vaccination. Vaccine, 39(29), 3790-
3793. doi:10.1016/j.vaccine.2021.05.087. https://www.ncbi.nlm.nih.gov/pubmed/34092429
878. Albert, E., Aurigemma, G., Saucedo, J., & Gerson, D. S. (2021). Myocarditis following
COVID-19 vaccination. Radiol Case Rep, 16(8), 2142-2145.
doi:10.1016/j.radcr.2021.05.033. https://www.ncbi.nlm.nih.gov/pubmed/34025885
879. Aye, Y. N., Mai, A. S., Zhang, A., Lim, O. Z. H., Lin, N., Ng, C. H., . . . Chew, N. W. S. (2021).
Acute Myocardial Infarction and Myocarditis following COVID-19 Vaccination. QJM.
doi:10.1093/qjmed/hcab252. https://www.ncbi.nlm.nih.gov/pubmed/34586408
880. Azir, M., Inman, B., Webb, J., & Tannenbaum, L. (2021). STEMI Mimic: Focal Myocarditis
in an Adolescent Patient After mRNA COVID-19 Vaccine. J Emerg Med, 61(6), e129-e132.
doi:10.1016/j.jemermed.2021.09.017. https://www.ncbi.nlm.nih.gov/pubmed/34756746
881. Barda, N., Dagan, N., Ben-Shlomo, Y., Kepten, E., Waxman, J., Ohana, R., . . . Balicer, R. D.
(2021). Safety of the BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Setting. N Engl J Med,
385(12), 1078-1090.
doi:10.1056/NEJMoa2110475. https://www.ncbi.nlm.nih.gov/pubmed/34432976
882. Bhandari, M., Pradhan, A., Vishwakarma, P., & Sethi, R. (2021). Coronavirus and
cardiovascular manifestations- getting to the heart of the matter. World J Cardiol, 13(10), 556-
565. doi:10.4330/wjc.v13.i10.556. https://www.ncbi.nlm.nih.gov/pubmed/34754400
883. Bozkurt, B., Kamat, I., & Hotez, P. J. (2021). Myocarditis With COVID-19 mRNA Vaccines.
Circulation, 144(6), 471-484.
doi:10.1161/CIRCULATIONAHA.121.056135. https://www.ncbi.nlm.nih.gov/pubmed/34281357
884. Buchhorn, R., Meyer, C., Schulze-Forster, K., Junker, J., & Heidecke, H. (2021).
Autoantibody Release in Children after Corona Virus mRNA Vaccination: A Risk Factor of
Multisystem Inflammatory Syndrome? Vaccines (Basel), 9(11).
doi:10.3390/vaccines9111353. https://www.ncbi.nlm.nih.gov/pubmed/34835284
885. Calcaterra, G., Bassareo, P. P., Barilla, F., Romeo, F., & Mehta, J. L. (2022). Concerning
the unexpected prothrombotic state following some coronavirus disease 2019 vaccines. J
Cardiovasc Med (Hagerstown), 23(2), 71-74.
doi:10.2459/JCM.0000000000001232. https://www.ncbi.nlm.nih.gov/pubmed/34366403
886. Calcaterra, G., Mehta, J. L., de Gregorio, C., Butera, G., Neroni, P., Fanos, V., & Bassareo,
P. P. (2021). COVID 19 Vaccine for Adolescents. Concern about Myocarditis and Pericarditis.
Pediatr Rep, 13(3), 530-533.
doi:10.3390/pediatric13030061. https://www.ncbi.nlm.nih.gov/pubmed/34564344
887. Chai, Q., Nygaard, U., Schmidt, R. C., Zaremba, T., Moller, A. M., & Thorvig, C. M. (2022).
Multisystem inflammatory syndrome in a male adolescent after his second Pfizer-BioNTech
COVID-19 vaccine. Acta Paediatr, 111(1), 125-127.
doi:10.1111/apa.16141. https://www.ncbi.nlm.nih.gov/pubmed/34617315
888. Chamling, B., Vehof, V., Drakos, S., Weil, M., Stalling, P., Vahlhaus, C., . . . Yilmaz, A.
(2021). Occurrence of acute infarct-like myocarditis following COVID-19 vaccination: just an
accidental co-incidence or rather vaccination-associated autoimmune myocarditis? Clin Res
Cardiol, 110(11), 1850-1854. doi:10.1007/s00392-021-01916-
w. https://www.ncbi.nlm.nih.gov/pubmed/34333695
890. Chelala, L., Jeudy, J., Hossain, R., Rosenthal, G., Pietris, N., & White, C. (2021). Cardiac
MRI Findings of Myocarditis After COVID-19 mRNA Vaccination in Adolescents. AJR Am J
Roentgenol. doi:10.2214/AJR.21.26853. https://www.ncbi.nlm.nih.gov/pubmed/34704459
891. Choi, S., Lee, S., Seo, J. W., Kim, M. J., Jeon, Y. H., Park, J. H., . . . Yeo, N. S. (2021).
Myocarditis-induced Sudden Death after BNT162b2 mRNA COVID-19 Vaccination in Korea: Case
Report Focusing on Histopathological Findings. J Korean Med Sci, 36(40), e286.
doi:10.3346/jkms.2021.36.e286. https://www.ncbi.nlm.nih.gov/pubmed/34664804
892. Chouchana, L., Blet, A., Al-Khalaf, M., Kafil, T. S., Nair, G., Robblee, J., . . . Liu, P. P.
(2021). Features of Inflammatory Heart Reactions Following mRNA COVID-19 Vaccination at a
Global Level. Clin Pharmacol Ther.
doi:10.1002/cpt.2499. https://www.ncbi.nlm.nih.gov/pubmed/34860360
893. Chua, G. T., Kwan, M. Y. W., Chui, C. S. L., Smith, R. D., Cheung, E. C., Tian, T., . . . Ip, P.
(2021). Epidemiology of Acute Myocarditis/Pericarditis in Hong Kong Adolescents Following
Comirnaty Vaccination. Clin Infect Dis.
doi:10.1093/cid/ciab989. https://www.ncbi.nlm.nih.gov/pubmed/34849657
894. Clarke, R., & Ioannou, A. (2021). Should T2 mapping be used in cases of recurrent
myocarditis to differentiate between the acute inflammation and chronic scar? J Pediatr.
doi:10.1016/j.jpeds.2021.12.026. https://www.ncbi.nlm.nih.gov/pubmed/34933012
895. Colaneri, M., De Filippo, M., Licari, A., Marseglia, A., Maiocchi, L., Ricciardi, A., . . . Bruno,
R. (2021). COVID vaccination and asthma exacerbation: might there be a link? Int J Infect Dis,
112, 243-246. doi:10.1016/j.ijid.2021.09.026. https://www.ncbi.nlm.nih.gov/pubmed/34547487
896. Das, B. B., Kohli, U., Ramachandran, P., Nguyen, H. H., Greil, G., Hussain, T., . . . Khan, D.
(2021). Myopericarditis after messenger RNA Coronavirus Disease 2019 Vaccination in
Adolescents 12 to 18 Years of Age. J Pediatr, 238, 26-32 e21.
doi:10.1016/j.jpeds.2021.07.044. https://www.ncbi.nlm.nih.gov/pubmed/34339728
897. Das, B. B., Moskowitz, W. B., Taylor, M. B., & Palmer, A. (2021). Myocarditis and
Pericarditis Following mRNA COVID-19 Vaccination: What Do We Know So Far? Children (Basel),
8(7). doi:10.3390/children8070607. https://www.ncbi.nlm.nih.gov/pubmed/34356586
898. Deb, A., Abdelmalek, J., Iwuji, K., & Nugent, K. (2021). Acute Myocardial Injury Following
COVID-19 Vaccination: A Case Report and Review of Current Evidence from Vaccine Adverse
Events Reporting System Database. J Prim Care Community Health, 12, 21501327211029230.
doi:10.1177/21501327211029230. https://www.ncbi.nlm.nih.gov/pubmed/34219532
899. Dickey, J. B., Albert, E., Badr, M., Laraja, K. M., Sena, L. M., Gerson, D. S., . . . Aurigemma,
G. P. (2021). A Series of Patients With Myocarditis Following SARS-CoV-2 Vaccination With
mRNA-1279 and BNT162b2. JACC Cardiovasc Imaging, 14(9), 1862-1863.
doi:10.1016/j.jcmg.2021.06.003. https://www.ncbi.nlm.nih.gov/pubmed/34246585
900. Dimopoulou, D., Spyridis, N., Vartzelis, G., Tsolia, M. N., & Maritsi, D. N. (2021). Safety
and tolerability of the COVID-19 mRNA-vaccine in adolescents with juvenile idiopathic arthritis
on treatment with TNF-inhibitors. Arthritis Rheumatol.
doi:10.1002/art.41977. https://www.ncbi.nlm.nih.gov/pubmed/34492161
901. Dimopoulou, D., Vartzelis, G., Dasoula, F., Tsolia, M., & Maritsi, D. (2021).
Immunogenicity of the COVID-19 mRNA vaccine in adolescents with juvenile idiopathic arthritis
on treatment with TNF inhibitors. Ann Rheum Dis. doi:10.1136/annrheumdis-2021-
221607. https://www.ncbi.nlm.nih.gov/pubmed/34844930
902. Ehrlich, P., Klingel, K., Ohlmann-Knafo, S., Huttinger, S., Sood, N., Pickuth, D., &
Kindermann, M. (2021). Biopsy-proven lymphocytic myocarditis following first mRNA COVID-19
vaccination in a 40-year-old male: case report. Clin Res Cardiol, 110(11), 1855-1859.
doi:10.1007/s00392-021-01936-6. https://www.ncbi.nlm.nih.gov/pubmed/34487236
903. El Sahly, H. M., Baden, L. R., Essink, B., Doblecki-Lewis, S., Martin, J. M., Anderson, E. J., .
. . Group, C. S. (2021). Efficacy of the mRNA-1273 SARS-CoV-2 Vaccine at Completion of Blinded
Phase. N Engl J Med, 385(19), 1774-1785.
doi:10.1056/NEJMoa2113017. https://www.ncbi.nlm.nih.gov/pubmed/34551225
904. Facetti, S., Giraldi, M., Vecchi, A. L., Rogiani, S., & Nassiacos, D. (2021). [Acute
myocarditis in a young adult two days after Pfizer vaccination]. G Ital Cardiol (Rome), 22(11),
891-893. doi:10.1714/3689.36746. https://www.ncbi.nlm.nih.gov/pubmed/34709227
905. Fazlollahi, A., Zahmatyar, M., Noori, M., Nejadghaderi, S. A., Sullman, M. J. M., Shekarriz-
Foumani, R., . . . Safiri, S. (2021). Cardiac complications following mRNA COVID-19 vaccines: A
systematic review of case reports and case series. Rev Med Virol, e2318.
doi:10.1002/rmv.2318. https://www.ncbi.nlm.nih.gov/pubmed/34921468
906. Fazolo, T., Lima, K., Fontoura, J. C., de Souza, P. O., Hilario, G., Zorzetto, R., . . . Bonorino,
C. (2021). Pediatric COVID-19 patients in South Brazil show abundant viral mRNA and strong
specific anti-viral responses. Nat Commun, 12(1), 6844. doi:10.1038/s41467-021-27120-
y. https://www.ncbi.nlm.nih.gov/pubmed/34824230
907. Fikenzer, S., & Laufs, U. (2021). Correction to: Response to Letter to the editors referring
to Fikenzer, S., Uhe, T., Lavall, D., Rudolph, U., Falz, R., Busse, M., Hepp, P., & Laufs, U. (2020).
Effects of surgical and FFP2/N95 face masks on cardiopulmonary exercise capacity. Clinical
research in cardiology: official journal of the German Cardiac Society, 1-9. Advance online
publication. https://doi.org/10.1007/s00392-020-01704-y. Clin Res Cardiol, 110(8), 1352.
doi:10.1007/s00392-021-01896-x. https://www.ncbi.nlm.nih.gov/pubmed/34170372
908. Foltran, D., Delmas, C., Flumian, C., De Paoli, P., Salvo, F., Gautier, S., . . . Montastruc, F.
(2021). Myocarditis and Pericarditis in Adolescents after First and Second doses of mRNA COVID-
19 Vaccines. Eur Heart J Qual Care Clin Outcomes.
doi:10.1093/ehjqcco/qcab090. https://www.ncbi.nlm.nih.gov/pubmed/34849667
909. Forgacs, D., Jang, H., Abreu, R. B., Hanley, H. B., Gattiker, J. L., Jefferson, A. M., & Ross, T.
M. (2021). SARS-CoV-2 mRNA Vaccines Elicit Different Responses in Immunologically Naive and
Pre-Immune Humans. Front Immunol, 12, 728021.
doi:10.3389/fimmu.2021.728021. https://www.ncbi.nlm.nih.gov/pubmed/34646267
910. Furer, V., Eviatar, T., Zisman, D., Peleg, H., Paran, D., Levartovsky, D., . . . Elkayam, O.
(2021). Immunogenicity and safety of the BNT162b2 mRNA COVID-19 vaccine in adult patients
with autoimmune inflammatory rheumatic diseases and in the general population: a multicentre
study. Ann Rheum Dis, 80(10), 1330-1338. doi:10.1136/annrheumdis-2021-
220647. https://www.ncbi.nlm.nih.gov/pubmed/34127481
911. Galindo, R., Chow, H., & Rongkavilit, C. (2021). COVID-19 in Children: Clinical
Manifestations and Pharmacologic Interventions Including Vaccine Trials. Pediatr Clin North Am,
68(5), 961-976.
doi:10.1016/j.pcl.2021.05.004. https://www.ncbi.nlm.nih.gov/pubmed/34538306
912. Gargano, J. W., Wallace, M., Hadler, S. C., Langley, G., Su, J. R., Oster, M. E., . . . Oliver, S.
E. (2021). Use of mRNA COVID-19 Vaccine After Reports of Myocarditis Among Vaccine
Recipients: Update from the Advisory Committee on Immunization Practices – United States,
June 2021. MMWR Morb Mortal Wkly Rep, 70(27), 977-982.
doi:10.15585/mmwr.mm7027e2. https://www.ncbi.nlm.nih.gov/pubmed/34237049
913. Gatti, M., Raschi, E., Moretti, U., Ardizzoni, A., Poluzzi, E., & Diemberger, I. (2021).
Influenza Vaccination and Myo-Pericarditis in Patients Receiving Immune Checkpoint Inhibitors:
Investigating the Likelihood of Interaction through the Vaccine Adverse Event Reporting System
and VigiBase. Vaccines (Basel), 9(1).
doi:10.3390/vaccines9010019. https://www.ncbi.nlm.nih.gov/pubmed/33406694
914. Gautam, N., Saluja, P., Fudim, M., Jambhekar, K., Pandey, T., & Al’Aref, S. (2021). A Late
Presentation of COVID-19 Vaccine-Induced Myocarditis. Cureus, 13(9), e17890.
doi:10.7759/cureus.17890. https://www.ncbi.nlm.nih.gov/pubmed/34660088
915. Gellad, W. F. (2021). Myocarditis after vaccination against covid-19. BMJ, 375, n3090.
doi:10.1136/bmj.n3090. https://www.ncbi.nlm.nih.gov/pubmed/34916217
916. Greenhawt, M., Abrams, E. M., Shaker, M., Chu, D. K., Khan, D., Akin, C., . . . Golden, D.
B. K. (2021). The Risk of Allergic Reaction to SARS-CoV-2 Vaccines and Recommended Evaluation
and Management: A Systematic Review, Meta-Analysis, GRADE Assessment, and International
Consensus Approach. J Allergy Clin Immunol Pract, 9(10), 3546-3567.
doi:10.1016/j.jaip.2021.06.006. https://www.ncbi.nlm.nih.gov/pubmed/34153517
917. Haaf, P., Kuster, G. M., Mueller, C., Berger, C. T., Monney, P., Burger, P., . . . Tanner, F. C.
(2021). The very low risk of myocarditis and pericarditis after mRNA COVID-19 vaccination
should not discourage vaccination. Swiss Med Wkly, 151, w30087.
doi:10.4414/smw.2021.w30087. https://www.ncbi.nlm.nih.gov/pubmed/34668687
918. Hasnie, A. A., Hasnie, U. A., Patel, N., Aziz, M. U., Xie, M., Lloyd, S. G., & Prabhu, S. D.
(2021). Perimyocarditis following first dose of the mRNA-1273 SARS-CoV-2 (Moderna) vaccine in
a healthy young male: a case report. BMC Cardiovasc Disord, 21(1), 375. doi:10.1186/s12872-
021-02183-3. https://www.ncbi.nlm.nih.gov/pubmed/34348657
919. Hause, A. M., Gee, J., Baggs, J., Abara, W. E., Marquez, P., Thompson, D., . . . Shay, D. K.
(2021). COVID-19 Vaccine Safety in Adolescents Aged 12-17 Years – United States, December 14,
2020-July 16, 2021. MMWR Morb Mortal Wkly Rep, 70(31), 1053-1058.
doi:10.15585/mmwr.mm7031e1. https://www.ncbi.nlm.nih.gov/pubmed/34351881
920. Helms, J. M., Ansteatt, K. T., Roberts, J. C., Kamatam, S., Foong, K. S., Labayog, J. S., &
Tarantino, M. D. (2021). Severe, Refractory Immune Thrombocytopenia Occurring After SARS-
CoV-2 Vaccine. J Blood Med, 12, 221-224.
doi:10.2147/JBM.S307047. https://www.ncbi.nlm.nih.gov/pubmed/33854395
921. Hippisley-Cox, J., Patone, M., Mei, X. W., Saatci, D., Dixon, S., Khunti, K., . . . Coupland, C.
A. C. (2021). Risk of thrombocytopenia and thromboembolism after covid-19 vaccination and
SARS-CoV-2 positive testing: self-controlled case series study. BMJ, 374, n1931.
doi:10.1136/bmj.n1931. https://www.ncbi.nlm.nih.gov/pubmed/34446426
922. Ho, J. S., Sia, C. H., Ngiam, J. N., Loh, P. H., Chew, N. W., Kong, W. K., & Poh, K. K. (2021).
A review of COVID-19 vaccination and the reported cardiac manifestations. Singapore Med J.
doi:10.11622/smedj.2021210. https://www.ncbi.nlm.nih.gov/pubmed/34808708
923. Iguchi, T., Umeda, H., Kojima, M., Kanno, Y., Tanaka, Y., Kinoshita, N., & Sato, D. (2021).
Cumulative Adverse Event Reporting of Anaphylaxis After mRNA COVID-19 Vaccine (Pfizer-
BioNTech) Injections in Japan: The First-Month Report. Drug Saf, 44(11), 1209-1214.
doi:10.1007/s40264-021-01104-9. https://www.ncbi.nlm.nih.gov/pubmed/34347278
924. In brief: Myocarditis with the Pfizer/BioNTech and Moderna COVID-19 vaccines. (2021).
Med Lett Drugs Ther, 63(1629), e9. Retrieved
from https://www.ncbi.nlm.nih.gov/pubmed/34544112https://www.ncbi.nlm.nih.gov/pubmed/
3454412
925. Ioannou, A. (2021a). Myocarditis should be considered in those with a troponin rise and
unobstructed coronary arteries following Pfizer-BioNTech COVID-19 vaccination. QJM.
doi:10.1093/qjmed/hcab231. https://www.ncbi.nlm.nih.gov/pubmed/34463755
927. Isaak, A., Feisst, A., & Luetkens, J. A. (2021). Myocarditis Following COVID-19
Vaccination. Radiology, 301(1), E378-E379.
doi:10.1148/radiol.2021211766. https://www.ncbi.nlm.nih.gov/pubmed/34342500
928. Istampoulouoglou, I., Dimitriou, G., Spani, S., Christ, A., Zimmermanns, B., Koechlin, S., .
. . Leuppi-Taegtmeyer, A. B. (2021). Myocarditis and pericarditis in association with COVID-19
mRNA-vaccination: cases from a regional pharmacovigilance centre. Glob Cardiol Sci Pract,
2021(3), e202118.
doi:10.21542/gcsp.2021.18. https://www.ncbi.nlm.nih.gov/pubmed/34805376
929. Jaafar, R., Boschi, C., Aherfi, S., Bancod, A., Le Bideau, M., Edouard, S., . . . La Scola, B.
(2021). High Individual Heterogeneity of Neutralizing Activities against the Original Strain and
Nine Different Variants of SARS-CoV-2. Viruses, 13(11).
doi:10.3390/v13112177. https://www.ncbi.nlm.nih.gov/pubmed/34834983
930. Jain, S. S., Steele, J. M., Fonseca, B., Huang, S., Shah, S., Maskatia, S. A., . . . Grosse-
Wortmann, L. (2021). COVID-19 Vaccination-Associated Myocarditis in Adolescents. Pediatrics,
148(5). doi:10.1542/peds.2021-053427. https://www.ncbi.nlm.nih.gov/pubmed/34389692
931. Jhaveri, R., Adler-Shohet, F. C., Blyth, C. C., Chiotos, K., Gerber, J. S., Green, M., . . .
Zaoutis, T. (2021). Weighing the Risks of Perimyocarditis With the Benefits of SARS-CoV-2 mRNA
Vaccination in Adolescents. J Pediatric Infect Dis Soc, 10(10), 937-939.
doi:10.1093/jpids/piab061. https://www.ncbi.nlm.nih.gov/pubmed/34270752
932. Kaneta, K., Yokoi, K., Jojima, K., Kotooka, N., & Node, K. (2021). Young Male With
Myocarditis Following mRNA-1273 Vaccination Against Coronavirus Disease-2019 (COVID-19).
Circ J. doi:10.1253/circj.CJ-21-0818. https://www.ncbi.nlm.nih.gov/pubmed/34744118
933. Kaul, R., Sreenivasan, J., Goel, A., Malik, A., Bandyopadhyay, D., Jin, C., . . . Panza, J. A.
(2021). Myocarditis following COVID-19 vaccination. Int J Cardiol Heart Vasc, 36, 100872.
doi:10.1016/j.ijcha.2021.100872. https://www.ncbi.nlm.nih.gov/pubmed/34568540
934. Khogali, F., & Abdelrahman, R. (2021). Unusual Presentation of Acute Perimyocarditis
Following SARS-COV-2 mRNA-1237 Moderna Vaccination. Cureus, 13(7), e16590.
doi:10.7759/cureus.16590. https://www.ncbi.nlm.nih.gov/pubmed/34447639
935. Kim, H. W., Jenista, E. R., Wendell, D. C., Azevedo, C. F., Campbell, M. J., Darty, S. N., . . .
Kim, R. J. (2021). Patients With Acute Myocarditis Following mRNA COVID-19 Vaccination. JAMA
Cardiol, 6(10), 1196-1201.
doi:10.1001/jamacardio.2021.2828. https://www.ncbi.nlm.nih.gov/pubmed/34185046
936. Kim, I. C., Kim, H., Lee, H. J., Kim, J. Y., & Kim, J. Y. (2021). Cardiac Imaging of Acute
Myocarditis Following COVID-19 mRNA Vaccination. J Korean Med Sci, 36(32), e229.
doi:10.3346/jkms.2021.36.e229. https://www.ncbi.nlm.nih.gov/pubmed/34402228
937. King, W. W., Petersen, M. R., Matar, R. M., Budweg, J. B., Cuervo Pardo, L., & Petersen, J.
W. (2021). Myocarditis following mRNA vaccination against SARS-CoV-2, a case series. Am Heart
J Plus, 8, 100042.
doi:10.1016/j.ahjo.2021.100042. https://www.ncbi.nlm.nih.gov/pubmed/34396358
938. Klein, N. P., Lewis, N., Goddard, K., Fireman, B., Zerbo, O., Hanson, K. E., . . . Weintraub,
E. S. (2021). Surveillance for Adverse Events After COVID-19 mRNA Vaccination. JAMA, 326(14),
1390-1399. doi:10.1001/jama.2021.15072. https://www.ncbi.nlm.nih.gov/pubmed/34477808
939. Klimek, L., Bergmann, K. C., Brehler, R., Pfutzner, W., Zuberbier, T., Hartmann, K., . . .
Worm, M. (2021). Practical handling of allergic reactions to COVID-19 vaccines: A position paper
from German and Austrian Allergy Societies AeDA, DGAKI, GPA and OGAI. Allergo J Int, 1-17.
doi:10.1007/s40629-021-00165-7. https://www.ncbi.nlm.nih.gov/pubmed/33898162
940. Klimek, L., Novak, N., Hamelmann, E., Werfel, T., Wagenmann, M., Taube, C., . . . Worm,
M. (2021). Severe allergic reactions after COVID-19 vaccination with the Pfizer/BioNTech vaccine
in Great Britain and USA: Position statement of the German Allergy Societies: Medical
Association of German Allergologists (AeDA), German Society for Allergology and Clinical
Immunology (DGAKI) and Society for Pediatric Allergology and Environmental Medicine (GPA).
Allergo J Int, 30(2), 51-55. doi:10.1007/s40629-020-00160-
4. https://www.ncbi.nlm.nih.gov/pubmed/33643776
941. Kohli, U., Desai, L., Chowdhury, D., Harahsheh, A. S., Yonts, A. B., Ansong, A., . . . Ang, J.
Y. (2021). mRNA Coronavirus-19 Vaccine-Associated Myopericarditis in Adolescents: A Survey
Study. J Pediatr.
doi:10.1016/j.jpeds.2021.12.025. https://www.ncbi.nlm.nih.gov/pubmed/34952008
942. Kostoff, R. N., Calina, D., Kanduc, D., Briggs, M. B., Vlachoyiannopoulos, P., Svistunov, A.
A., & Tsatsakis, A. (2021a). Erratum to “Why are we vaccinating children against COVID-19?”
[Toxicol. Rep. 8C (2021) 1665-1684 / 1193]. Toxicol Rep, 8, 1981.
doi:10.1016/j.toxrep.2021.10.003. https://www.ncbi.nlm.nih.gov/pubmed/34642628
943. Kostoff, R. N., Calina, D., Kanduc, D., Briggs, M. B., Vlachoyiannopoulos, P., Svistunov, A.
A., & Tsatsakis, A. (2021b). Why are we vaccinating children against COVID-19? Toxicol Rep, 8,
1665-1684.
doi:10.1016/j.toxrep.2021.08.010. https://www.ncbi.nlm.nih.gov/pubmed/34540594
944. Kremsner, P. G., Mann, P., Kroidl, A., Leroux-Roels, I., Schindler, C., Gabor, J. J., . . .
Group, C.-N.-S. (2021). Safety and immunogenicity of an mRNA-lipid nanoparticle vaccine
candidate against SARS-CoV-2 : A phase 1 randomized clinical trial. Wien Klin Wochenschr,
133(17-18), 931-941. doi:10.1007/s00508-021-01922-
y. https://www.ncbi.nlm.nih.gov/pubmed/34378087
945. Kustin, T., Harel, N., Finkel, U., Perchik, S., Harari, S., Tahor, M., . . . Stern, A. (2021).
Evidence for increased breakthrough rates of SARS-CoV-2 variants of concern in BNT162b2-
mRNA-vaccinated individuals. Nat Med, 27(8), 1379-1384. doi:10.1038/s41591-021-01413-
7. https://www.ncbi.nlm.nih.gov/pubmed/34127854
946. Kwan, M. Y. W., Chua, G. T., Chow, C. B., Tsao, S. S. L., To, K. K. W., Yuen, K. Y., . . . Ip, P.
(2021). mRNA COVID vaccine and myocarditis in adolescents. Hong Kong Med J, 27(5), 326-327.
doi:10.12809/hkmj215120. https://www.ncbi.nlm.nih.gov/pubmed/34393110
947. Lee, E., Chew, N. W. S., Ng, P., & Yeo, T. J. (2021). Reply to “Letter to the editor:
Myocarditis should be considered in those with a troponin rise and unobstructed coronary
arteries following PfizerBioNTech COVID-19 vaccination”. QJM.
doi:10.1093/qjmed/hcab232. https://www.ncbi.nlm.nih.gov/pubmed/34463770
948. Lee, E. J., Cines, D. B., Gernsheimer, T., Kessler, C., Michel, M., Tarantino, M. D., . . .
Bussel, J. B. (2021). Thrombocytopenia following Pfizer and Moderna SARS-CoV-2 vaccination.
Am J Hematol, 96(5), 534-537.
doi:10.1002/ajh.26132. https://www.ncbi.nlm.nih.gov/pubmed/33606296
949. Levin, D., Shimon, G., Fadlon-Derai, M., Gershovitz, L., Shovali, A., Sebbag, A., . . .
Gordon, B. (2021). Myocarditis following COVID-19 vaccination – A case series. Vaccine, 39(42),
6195-6200.
doi:10.1016/j.vaccine.2021.09.004. https://www.ncbi.nlm.nih.gov/pubmed/34535317
950. Li, J., Hui, A., Zhang, X., Yang, Y., Tang, R., Ye, H., . . . Zhu, F. (2021). Safety and
immunogenicity of the SARS-CoV-2 BNT162b1 mRNA vaccine in younger and older Chinese
adults: a randomized, placebo-controlled, double-blind phase 1 study. Nat Med, 27(6), 1062-
1070. doi:10.1038/s41591-021-01330-9. https://www.ncbi.nlm.nih.gov/pubmed/33888900
951. Li, M., Yuan, J., Lv, G., Brown, J., Jiang, X., & Lu, Z. K. (2021). Myocarditis and Pericarditis
following COVID-19 Vaccination: Inequalities in Age and Vaccine Types. J Pers Med, 11(11).
doi:10.3390/jpm11111106. https://www.ncbi.nlm.nih.gov/pubmed/34834458
952. Lim, Y., Kim, M. C., Kim, K. H., Jeong, I. S., Cho, Y. S., Choi, Y. D., & Lee, J. E. (2021). Case
Report: Acute Fulminant Myocarditis and Cardiogenic Shock After Messenger RNA Coronavirus
Disease 2019 Vaccination Requiring Extracorporeal Cardiopulmonary Resuscitation. Front
Cardiovasc Med, 8, 758996.
doi:10.3389/fcvm.2021.758996. https://www.ncbi.nlm.nih.gov/pubmed/34778411
953. Long, S. S. (2021). Important Insights into Myopericarditis after the Pfizer mRNA COVID-
19 Vaccination in Adolescents. J Pediatr, 238, 5.
doi:10.1016/j.jpeds.2021.07.057. https://www.ncbi.nlm.nih.gov/pubmed/34332972
954. Luk, A., Clarke, B., Dahdah, N., Ducharme, A., Krahn, A., McCrindle, B., . . . McDonald, M.
(2021). Myocarditis and Pericarditis After COVID-19 mRNA Vaccination: Practical Considerations
for Care Providers. Can J Cardiol, 37(10), 1629-1634.
doi:10.1016/j.cjca.2021.08.001. https://www.ncbi.nlm.nih.gov/pubmed/34375696
955. Madelon, N., Lauper, K., Breville, G., Sabater Royo, I., Goldstein, R., Andrey, D. O., . . .
Eberhardt, C. S. (2021). Robust T cell responses in anti-CD20 treated patients following COVID-
19 vaccination: a prospective cohort study. Clin Infect Dis.
doi:10.1093/cid/ciab954. https://www.ncbi.nlm.nih.gov/pubmed/34791081
956. Mangat, C., & Milosavljevic, N. (2021). BNT162b2 Vaccination during Pregnancy Protects
Both the Mother and Infant: Anti-SARS-CoV-2 S Antibodies Persistently Positive in an Infant at 6
Months of Age. Case Rep Pediatr, 2021, 6901131.
doi:10.1155/2021/6901131. https://www.ncbi.nlm.nih.gov/pubmed/34676123
957. Mark, C., Gupta, S., Punnett, A., Upton, J., Orkin, J., Atkinson, A., . . . Alexander, S.
(2021). Safety of administration of BNT162b2 mRNA (Pfizer-BioNTech) COVID-19 vaccine in
youths and young adults with a history of acute lymphoblastic leukemia and allergy to PEG-
asparaginase. Pediatr Blood Cancer, 68(11), e29295.
doi:10.1002/pbc.29295. https://www.ncbi.nlm.nih.gov/pubmed/34398511
958. Martins-Filho, P. R., Quintans-Junior, L. J., de Souza Araujo, A. A., Sposato, K. B., Souza
Tavares, C. S., Gurgel, R. Q., . . . Santos, V. S. (2021). Socio-economic inequalities and COVID-19
incidence and mortality in Brazilian children: a nationwide register-based study. Public Health,
190, 4-6. doi:10.1016/j.puhe.2020.11.005. https://www.ncbi.nlm.nih.gov/pubmed/33316478
959. McLean, K., & Johnson, T. J. (2021). Myopericarditis in a previously healthy adolescent
male following COVID-19 vaccination: A case report. Acad Emerg Med, 28(8), 918-921.
doi:10.1111/acem.14322. https://www.ncbi.nlm.nih.gov/pubmed/34133825
960. Mevorach, D., Anis, E., Cedar, N., Bromberg, M., Haas, E. J., Nadir, E., . . . Alroy-Preis, S.
(2021). Myocarditis after BNT162b2 mRNA Vaccine against Covid-19 in Israel. N Engl J Med,
385(23), 2140-2149.
doi:10.1056/NEJMoa2109730. https://www.ncbi.nlm.nih.gov/pubmed/34614328
961. Minocha, P. K., Better, D., Singh, R. K., & Hoque, T. (2021). Recurrence of Acute
Myocarditis Temporally Associated with Receipt of the mRNA Coronavirus Disease 2019 (COVID-
19) Vaccine in a Male Adolescent. J Pediatr, 238, 321-323.
doi:10.1016/j.jpeds.2021.06.035. https://www.ncbi.nlm.nih.gov/pubmed/34166671
962. Mizrahi, B., Lotan, R., Kalkstein, N., Peretz, A., Perez, G., Ben-Tov, A., . . . Patalon, T.
(2021). Correlation of SARS-CoV-2-breakthrough infections to time-from-vaccine. Nat Commun,
12(1), 6379. doi:10.1038/s41467-021-26672-
3. https://www.ncbi.nlm.nih.gov/pubmed/34737312
963. Moffitt, K., Cheung, E., Yeung, T., Stamoulis, C., & Malley, R. (2021). Analysis of
Staphylococcus aureus Transcriptome in Pediatric Soft Tissue Abscesses and Comparison to
Murine Infections. Infect Immun, 89(4). doi:10.1128/IAI.00715-
20. https://www.ncbi.nlm.nih.gov/pubmed/33526560
964. Mohamed, L., Madsen, A. M. R., Schaltz-Buchholzer, F., Ostenfeld, A., Netea, M. G.,
Benn, C. S., & Kofoed, P. E. (2021). Reactivation of BCG vaccination scars after vaccination with
mRNA-Covid-vaccines: two case reports. BMC Infect Dis, 21(1), 1264. doi:10.1186/s12879-021-
06949-0. https://www.ncbi.nlm.nih.gov/pubmed/34930152
965. Montgomery, J., Ryan, M., Engler, R., Hoffman, D., McClenathan, B., Collins, L., . . .
Cooper, L. T., Jr. (2021). Myocarditis Following Immunization With mRNA COVID-19 Vaccines in
Members of the US Military. JAMA Cardiol, 6(10), 1202-1206.
doi:10.1001/jamacardio.2021.2833. https://www.ncbi.nlm.nih.gov/pubmed/34185045
966. Murakami, Y., Shinohara, M., Oka, Y., Wada, R., Noike, R., Ohara, H., . . . Ikeda, T. (2021).
Myocarditis Following a COVID-19 Messenger RNA Vaccination: A Japanese Case Series. Intern
Med. doi:10.2169/internalmedicine.8731-21. https://www.ncbi.nlm.nih.gov/pubmed/34840235
967. Nagasaka, T., Koitabashi, N., Ishibashi, Y., Aihara, K., Takama, N., Ohyama, Y., . . .
Kaneko, Y. (2021). Acute Myocarditis Associated with COVID-19 Vaccination: A Case Report. J
Cardiol Cases.
doi:10.1016/j.jccase.2021.11.006. https://www.ncbi.nlm.nih.gov/pubmed/34876937
968. Ntouros, P. A., Vlachogiannis, N. I., Pappa, M., Nezos, A., Mavragani, C. P., Tektonidou,
M. G., . . . Sfikakis, P. P. (2021). Effective DNA damage response after acute but not chronic
immune challenge: SARS-CoV-2 vaccine versus Systemic Lupus Erythematosus. Clin Immunol,
229, 108765.
doi:10.1016/j.clim.2021.108765. https://www.ncbi.nlm.nih.gov/pubmed/34089859
969. Nygaard, U., Holm, M., Bohnstedt, C., Chai, Q., Schmidt, L. S., Hartling, U. B., . . .
Stensballe, L. G. (2022). Population-based Incidence of Myopericarditis After COVID-19
Vaccination in Danish Adolescents. Pediatr Infect Dis J, 41(1), e25-e28.
doi:10.1097/INF.0000000000003389. https://www.ncbi.nlm.nih.gov/pubmed/34889875
970. Oberhardt, V., Luxenburger, H., Kemming, J., Schulien, I., Ciminski, K., Giese, S., . . .
Hofmann, M. (2021). Rapid and stable mobilization of CD8(+) T cells by SARS-CoV-2 mRNA
vaccine. Nature, 597(7875), 268-273. doi:10.1038/s41586-021-03841-
4. https://www.ncbi.nlm.nih.gov/pubmed/34320609
971. Park, H., Yun, K. W., Kim, K. R., Song, S. H., Ahn, B., Kim, D. R., . . . Kim, Y. J. (2021).
Epidemiology and Clinical Features of Myocarditis/Pericarditis before the Introduction of mRNA
COVID-19 Vaccine in Korean Children: a Multicenter Study. J Korean Med Sci, 36(32), e232.
doi:10.3346/jkms.2021.36.e232. https://www.ncbi.nlm.nih.gov/pubmed/34402230
972. Park, J., Brekke, D. R., & Bratincsak, A. (2021). Self-limited myocarditis presenting with
chest pain and ST segment elevation in adolescents after vaccination with the BNT162b2 mRNA
vaccine. Cardiol Young, 1-4.
doi:10.1017/S1047951121002547. https://www.ncbi.nlm.nih.gov/pubmed/34180390
973. Patel, Y. R., Louis, D. W., Atalay, M., Agarwal, S., & Shah, N. R. (2021). Cardiovascular
magnetic resonance findings in young adult patients with acute myocarditis following mRNA
COVID-19 vaccination: a case series. J Cardiovasc Magn Reson, 23(1), 101. doi:10.1186/s12968-
021-00795-4. https://www.ncbi.nlm.nih.gov/pubmed/34496880
974. Patone, M., Mei, X. W., Handunnetthi, L., Dixon, S., Zaccardi, F., Shankar-Hari, M., . . .
Hippisley-Cox, J. (2021). Risks of myocarditis, pericarditis, and cardiac arrhythmias associated
with COVID-19 vaccination or SARS-CoV-2 infection. Nat Med. doi:10.1038/s41591-021-01630-
0. https://www.ncbi.nlm.nih.gov/pubmed/34907393
975. Patrignani, A., Schicchi, N., Calcagnoli, F., Falchetti, E., Ciampani, N., Argalia, G., &
Mariani, A. (2021). Acute myocarditis following Comirnaty vaccination in a healthy man with
previous SARS-CoV-2 infection. Radiol Case Rep, 16(11), 3321-3325.
doi:10.1016/j.radcr.2021.07.082. https://www.ncbi.nlm.nih.gov/pubmed/34367386
976. Perez, Y., Levy, E. R., Joshi, A. Y., Virk, A., Rodriguez-Porcel, M., Johnson, M., . . . Swift,
M. D. (2021). Myocarditis Following COVID-19 mRNA Vaccine: A Case Series and Incidence Rate
Determination. Clin Infect Dis.
doi:10.1093/cid/ciab926. https://www.ncbi.nlm.nih.gov/pubmed/34734240
977. Perrotta, A., Biondi-Zoccai, G., Saade, W., Miraldi, F., Morelli, A., Marullo, A. G., . . .
Peruzzi, M. (2021). A snapshot global survey on side effects of COVID-19 vaccines among
healthcare professionals and armed forces with a focus on headache. Panminerva Med, 63(3),
324-331. doi:10.23736/S0031-0808.21.04435-
9. https://www.ncbi.nlm.nih.gov/pubmed/34738774
978. Pinana, J. L., Lopez-Corral, L., Martino, R., Montoro, J., Vazquez, L., Perez, A., . . . Cell
Therapy, G. (2022). SARS-CoV-2-reactive antibody detection after SARS-CoV-2 vaccination in
hematopoietic stem cell transplant recipients: Prospective survey from the Spanish
Hematopoietic Stem Cell Transplantation and Cell Therapy Group. Am J Hematol, 97(1), 30-42.
doi:10.1002/ajh.26385. https://www.ncbi.nlm.nih.gov/pubmed/34695229
979. Revon-Riviere, G., Ninove, L., Min, V., Rome, A., Coze, C., Verschuur, A., . . . Andre, N.
(2021). The BNT162b2 mRNA COVID-19 vaccine in adolescents and young adults with cancer: A
monocentric experience. Eur J Cancer, 154, 30-34.
doi:10.1016/j.ejca.2021.06.002. https://www.ncbi.nlm.nih.gov/pubmed/34233234
980. Sanchez Tijmes, F., Thavendiranathan, P., Udell, J. A., Seidman, M. A., & Hanneman, K.
(2021). Cardiac MRI Assessment of Nonischemic Myocardial Inflammation: State of the Art
Review and Update on Myocarditis Associated with COVID-19 Vaccination. Radiol Cardiothorac
Imaging, 3(6), e210252.
doi:10.1148/ryct.210252. https://www.ncbi.nlm.nih.gov/pubmed/34934954
981. Schauer, J., Buddhe, S., Colyer, J., Sagiv, E., Law, Y., Mallenahalli Chikkabyrappa, S., &
Portman, M. A. (2021). Myopericarditis After the Pfizer Messenger Ribonucleic Acid Coronavirus
Disease Vaccine in Adolescents. J Pediatr, 238, 317-320.
doi:10.1016/j.jpeds.2021.06.083. https://www.ncbi.nlm.nih.gov/pubmed/34228985
982. Schneider, J., Sottmann, L., Greinacher, A., Hagen, M., Kasper, H. U., Kuhnen, C., . . .
Schmeling, A. (2021). Postmortem investigation of fatalities following vaccination with COVID-19
vaccines. Int J Legal Med, 135(6), 2335-2345. doi:10.1007/s00414-021-02706-
9. https://www.ncbi.nlm.nih.gov/pubmed/34591186
983. Schramm, R., Costard-Jackle, A., Rivinius, R., Fischer, B., Muller, B., Boeken, U., . . .
Gummert, J. (2021). Poor humoral and T-cell response to two-dose SARS-CoV-2 messenger RNA
vaccine BNT162b2 in cardiothoracic transplant recipients. Clin Res Cardiol, 110(8), 1142-1149.
doi:10.1007/s00392-021-01880-5. https://www.ncbi.nlm.nih.gov/pubmed/34241676
984. Sessa, F., Salerno, M., Esposito, M., Di Nunno, N., Zamboni, P., & Pomara, C. (2021).
Autopsy Findings and Causality Relationship between Death and COVID-19 Vaccination: A
Systematic Review. J Clin Med, 10(24).
doi:10.3390/jcm10245876. https://www.ncbi.nlm.nih.gov/pubmed/34945172
985. Sharif, N., Alzahrani, K. J., Ahmed, S. N., & Dey, S. K. (2021). Efficacy, Immunogenicity
and Safety of COVID-19 Vaccines: A Systematic Review and Meta-Analysis. Front Immunol, 12,
714170. doi:10.3389/fimmu.2021.714170. https://www.ncbi.nlm.nih.gov/pubmed/34707602
986. Shay, D. K., Gee, J., Su, J. R., Myers, T. R., Marquez, P., Liu, R., . . . Shimabukuro, T. T.
(2021). Safety Monitoring of the Janssen (Johnson & Johnson) COVID-19 Vaccine – United
States, March-April 2021. MMWR Morb Mortal Wkly Rep, 70(18), 680-684.
doi:10.15585/mmwr.mm7018e2. https://www.ncbi.nlm.nih.gov/pubmed/33956784
987. Shazley, O., & Alshazley, M. (2021). A COVID-Positive 52-Year-Old Man Presented With
Venous Thromboembolism and Disseminated Intravascular Coagulation Following Johnson &
Johnson Vaccination: A Case-Study. Cureus, 13(7), e16383.
doi:10.7759/cureus.16383. https://www.ncbi.nlm.nih.gov/pubmed/34408937
988. Shiyovich, A., Witberg, G., Aviv, Y., Eisen, A., Orvin, K., Wiessman, M., . . . Hamdan, A.
(2021). Myocarditis following COVID-19 vaccination: magnetic resonance imaging study. Eur
Heart J Cardiovasc Imaging.
doi:10.1093/ehjci/jeab230. https://www.ncbi.nlm.nih.gov/pubmed/34739045
989. Simone, A., Herald, J., Chen, A., Gulati, N., Shen, A. Y., Lewin, B., & Lee, M. S. (2021).
Acute Myocarditis Following COVID-19 mRNA Vaccination in Adults Aged 18 Years or Older.
JAMA Intern Med, 181(12), 1668-1670.
doi:10.1001/jamainternmed.2021.5511. https://www.ncbi.nlm.nih.gov/pubmed/34605853
990. Singer, M. E., Taub, I. B., & Kaelber, D. C. (2021). Risk of Myocarditis from COVID-19
Infection in People Under Age 20: A Population-Based Analysis. medRxiv.
doi:10.1101/2021.07.23.21260998. https://www.ncbi.nlm.nih.gov/pubmed/34341797
991. Smith, C., Odd, D., Harwood, R., Ward, J., Linney, M., Clark, M., . . . Fraser, L. K. (2021).
Deaths in children and young people in England after SARS-CoV-2 infection during the first
pandemic year. Nat Med. doi:10.1038/s41591-021-01578-
1. https://www.ncbi.nlm.nih.gov/pubmed/34764489
992. Snapiri, O., Rosenberg Danziger, C., Shirman, N., Weissbach, A., Lowenthal, A., Ayalon, I.,
. . . Bilavsky, E. (2021). Transient Cardiac Injury in Adolescents Receiving the BNT162b2 mRNA
COVID-19 Vaccine. Pediatr Infect Dis J, 40(10), e360-e363.
doi:10.1097/INF.0000000000003235. https://www.ncbi.nlm.nih.gov/pubmed/34077949
993. Spinner, J. A., Julien, C. L., Olayinka, L., Dreyer, W. J., Bocchini, C. E., Munoz, F. M., &
Devaraj, S. (2021). SARS-CoV-2 anti-spike antibodies after vaccination in pediatric heart
transplantation: A first report. J Heart Lung Transplant.
doi:10.1016/j.healun.2021.11.001. https://www.ncbi.nlm.nih.gov/pubmed/34911654
994. Starekova, J., Bluemke, D. A., Bradham, W. S., Grist, T. M., Schiebler, M. L., & Reeder, S.
B. (2021). Myocarditis Associated with mRNA COVID-19 Vaccination. Radiology, 301(2), E409-
E411. doi:10.1148/radiol.2021211430. https://www.ncbi.nlm.nih.gov/pubmed/34282971
995. Sulemankhil, I., Abdelrahman, M., & Negi, S. I. (2021). Temporal association between
the COVID-19 Ad26.COV2.S vaccine and acute myocarditis: A case report and literature review.
Cardiovasc Revasc Med.
doi:10.1016/j.carrev.2021.08.012. https://www.ncbi.nlm.nih.gov/pubmed/34420869
996. Tailor, P. D., Feighery, A. M., El-Sabawi, B., & Prasad, A. (2021). Case report: acute
myocarditis following the second dose of mRNA-1273 SARS-CoV-2 vaccine. Eur Heart J Case Rep,
5(8), ytab319. doi:10.1093/ehjcr/ytab319. https://www.ncbi.nlm.nih.gov/pubmed/34514306
997. Takeda, M., Ishio, N., Shoji, T., Mori, N., Matsumoto, M., & Shikama, N. (2021).
Eosinophilic Myocarditis Following Coronavirus Disease 2019 (COVID-19) Vaccination. Circ J.
doi:10.1253/circj.CJ-21-0935. https://www.ncbi.nlm.nih.gov/pubmed/34955479
998. Team, C. C.-R., Food, & Drug, A. (2021). Allergic Reactions Including Anaphylaxis After
Receipt of the First Dose of Pfizer-BioNTech COVID-19 Vaccine – United States, December 14-23,
2020. MMWR Morb Mortal Wkly Rep, 70(2), 46-51.
doi:10.15585/mmwr.mm7002e1. https://www.ncbi.nlm.nih.gov/pubmed/33444297
999. Thompson, M. G., Burgess, J. L., Naleway, A. L., Tyner, H., Yoon, S. K., Meece, J., . . .
Gaglani, M. (2021). Prevention and Attenuation of Covid-19 with the BNT162b2 and mRNA-1273
Vaccines. N Engl J Med, 385(4), 320-329.
doi:10.1056/NEJMoa2107058. https://www.ncbi.nlm.nih.gov/pubmed/34192428
1000. Tinoco, M., Leite, S., Faria, B., Cardoso, S., Von Hafe, P., Dias, G., . . . Lourenco, A. (2021).
Perimyocarditis Following COVID-19 Vaccination. Clin Med Insights Cardiol, 15,
11795468211056634.
doi:10.1177/11795468211056634. https://www.ncbi.nlm.nih.gov/pubmed/34866957
1001. Truong, D. T., Dionne, A., Muniz, J. C., McHugh, K. E., Portman, M. A., Lambert, L. M., . . .
Newburger, J. W. (2021). Clinically Suspected Myocarditis Temporally Related to COVID-19
Vaccination in Adolescents and Young Adults. Circulation.
doi:10.1161/CIRCULATIONAHA.121.056583. https://www.ncbi.nlm.nih.gov/pubmed/34865500
1002. Tutor, A., Unis, G., Ruiz, B., Bolaji, O. A., & Bob-Manuel, T. (2021). Spectrum of
Suspected Cardiomyopathy Due to COVID-19: A Case Series. Curr Probl Cardiol, 46(10), 100926.
doi:10.1016/j.cpcardiol.2021.100926. https://www.ncbi.nlm.nih.gov/pubmed/34311983
1003. Umei, T. C., Kishino, Y., Shiraishi, Y., Inohara, T., Yuasa, S., & Fukuda, K. (2021).
Recurrence of myopericarditis following mRNA COVID-19 vaccination in a male adolescent. CJC
Open. doi:10.1016/j.cjco.2021.12.002. https://www.ncbi.nlm.nih.gov/pubmed/34904134
1004. Vidula, M. K., Ambrose, M., Glassberg, H., Chokshi, N., Chen, T., Ferrari, V. A., & Han, Y.
(2021). Myocarditis and Other Cardiovascular Complications of the mRNA-Based COVID-19
Vaccines. Cureus, 13(6), e15576.
doi:10.7759/cureus.15576. https://www.ncbi.nlm.nih.gov/pubmed/34277198
1005. Visclosky, T., Theyyunni, N., Klekowski, N., & Bradin, S. (2021). Myocarditis Following
mRNA COVID-19 Vaccine. Pediatr Emerg Care, 37(11), 583-584.
doi:10.1097/PEC.0000000000002557. https://www.ncbi.nlm.nih.gov/pubmed/34731877
1006. Warren, C. M., Snow, T. T., Lee, A. S., Shah, M. M., Heider, A., Blomkalns, A., . . . Nadeau,
K. C. (2021). Assessment of Allergic and Anaphylactic Reactions to mRNA COVID-19 Vaccines
With Confirmatory Testing in a US Regional Health System. JAMA Netw Open, 4(9), e2125524.
doi:10.1001/jamanetworkopen.2021.25524. https://www.ncbi.nlm.nih.gov/pubmed/34533570
1007. Watkins, K., Griffin, G., Septaric, K., & Simon, E. L. (2021). Myocarditis after BNT162b2
vaccination in a healthy male. Am J Emerg Med, 50, 815 e811-815 e812.
doi:10.1016/j.ajem.2021.06.051. https://www.ncbi.nlm.nih.gov/pubmed/34229940
1008. Weitzman, E. R., Sherman, A. C., & Levy, O. (2021). SARS-CoV-2 mRNA Vaccine Attitudes
as Expressed in U.S. FDA Public Commentary: Need for a Public-Private Partnership in a Learning
Immunization System. Front Public Health, 9, 695807.
doi:10.3389/fpubh.2021.695807. https://www.ncbi.nlm.nih.gov/pubmed/34336774
1009. Welsh, K. J., Baumblatt, J., Chege, W., Goud, R., & Nair, N. (2021). Thrombocytopenia
including immune thrombocytopenia after receipt of mRNA COVID-19 vaccines reported to the
Vaccine Adverse Event Reporting System (VAERS). Vaccine, 39(25), 3329-3332.
doi:10.1016/j.vaccine.2021.04.054. https://www.ncbi.nlm.nih.gov/pubmed/34006408
1010. Witberg, G., Barda, N., Hoss, S., Richter, I., Wiessman, M., Aviv, Y., . . . Kornowski, R.
(2021). Myocarditis after Covid-19 Vaccination in a Large Health Care Organization. N Engl J
Med, 385(23), 2132-2139.
doi:10.1056/NEJMoa2110737. https://www.ncbi.nlm.nih.gov/pubmed/34614329
1011. Zimmermann, P., & Curtis, N. (2020). Why is COVID-19 less severe in children? A review
of the proposed mechanisms underlying the age-related difference in severity of SARS-CoV-2
infections. Arch Dis Child. doi:10.1136/archdischild-2020-
320338. https://www.ncbi.nlm.nih.gov/pubmed/33262177